5-HT₃ Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface

Gohar Fakhfouri,¹ Reza Rahimian,¹ Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu

Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.)

Abstract

I. Introduction

II. 5-HT₃ Receptor Structure, Distribution, and Ligands

A. 5-HT₃ Receptor Agonists
B. 5-HT₃ Receptor Antagonists
   1. 5-HT₃ Receptor Competitive Antagonists
   2. 5-HT₃ Receptor Noncompetitive Antagonists
C. 5-HT₃ Receptor Allosteric Modulators
D. 5-HT₃ Receptor Ligands and Cholinergic System Modulation
   1. Dual 5-HT₃ Receptor Antagonist/Cholinesterase Inhibitors
   2. Dual 5-HT₃ Receptor Antagonists/Nicotinic Receptor Agonists

III. Biologic Effects of 5-HT₃ Receptor Antagonists, a Final Remark

IV. 5-HT₃ Receptor Antagonists in Neurologic Disorders

A. Seizure
B. Neurotoxicity Associated with Cancer Chemotherapy Drugs
C. Central Component of Irritable Bowel Syndrome
D. Memory Disorders
E. Inner Ear Diseases
F. Stroke
   1. Modulation of Molecular Pathways
   2. Possible Effects on Microglia
   3. Effect on Diabetes and Glucose Intolerance as Risk Factors for Stroke

V. 5-HT₃ Receptor Antagonists in Psychiatric Disorders

A. Depression
   1. Modulation of Putative Neuropathology
   2. Pharmacological Action of Antidepressants on 5-HT₃ Receptors
   3. Human Genetic Findings
B. Anxiety
   1. Human Genetic Findings
   2. Obsessive-Compulsive Disorder
      a. Clinical Findings
      b. Human Genetic Findings
   3. Post-Traumatic Stress Disorder, a Different Case

Address correspondence to: Dr. Jean-Martin Beaulieu, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Medical Science Building, Toronto, ON M5S 1A8, Canada. E-mail: martin.beaulieu@utoronto.ca

This work was supported by grants from the Canadian Institutes of Health Research (CIHR) to J.M.-B. J.M.-B. holds a Canada Research Chair (Tier 1) in Molecular Psychiatry.

¹G.F. and R.R. contributed equally to this work.

https://doi.org/10.1124/pr.118.015487.
Abstract—5-HT₃ receptor antagonists, first introduced to the market in the mid-1980s, are proven efficient agents to counteract chemotherapy-induced emesis. Nonetheless, recent investigations have shed light on unappreciated dimensions of this class of compounds in conditions with an immunoinflammatory component as well as in neurologic and psychiatric disorders. The promising findings from multiple studies have unveiled several beneficial effects of these compounds in multiple sclerosis, stroke, Alzheimer disease, and Parkinson disease. Reports continue to uncover important roles for 5-HT₃ receptors in the physiopathology of neuropsychiatric disorders, including depression, anxiety, drug abuse, and schizophrenia. This review addresses the potential of 5-HT₃ receptor antagonists in neurology- and neuropsychiatry-related disorders. The broad therapeutic window and high compliance observed with these agents position them as suitable prototypes for the development of novel pharmacotherapeutics with higher efficacy and fewer adverse effects.

I. Introduction

The monoamine serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter engaged in the regulation of a broad spectrum of peripheral and central functions ranging from immunity, gastrointestinal physiology, sexual behavior, and appetite to activity rhythms, pain sensation, mood, emotional states, and cognition (Buhot et al., 2000; Baganz and Blakely, 2013). The diversity and specificity of the various actions of 5-HT arise from the diversity of 5-HT receptor subtypes. The 5-HT₃ receptor (5-HT₃R) occupies a unique place among 5-HTRs because it is the only serotonin-gated cation channel mediating fast excitatory responses, whereas other 5-HT receptor subtypes are coupled to G proteins (Yakel and Jackson, 1988; Maricq et al., 1991). The advent of 5-HT₃R antagonists was a major advancement in the prevention of antineoplastic chemotherapy-induced nausea and vomiting. However, the wide distribution of 5-HT₃R expression suggests that ligands acting on these receptors should have several additional effects that could be of therapeutic interest. Indeed, many recent studies have shown potential effects of 5-HT₃R antagonists in an array of inflammatory, neurodegenerative, and psychiatric diseases. This is of particular clinical relevance since many of these disorders have unmet therapeutic needs due to the inadequate effectiveness and/or multiple unwanted effects by conventional medications, which compromise patient compliance and therefore the success rate of pharmacotherapy.

In this comprehensive review, we discuss 5-HT₃Rs and their expression pattern and structural organization. In addition, we discuss the potential utility of pharmacological agents acting as 5-HT₃R antagonists for the treatment of neuropathologies as diverse as seizure, stroke, memory disorders, inner ear diseases, schizophrenia, depression, anxiety disorders, and drug addiction. In doing so, we will pay special attention not only to effects that can be mediated by 5-HT₃Rs but also to complementary effects that could be explained by an action of these compounds on additional pharmacological targets.

II. 5-HT₃ Receptor Structure, Distribution, and Ligands

The structure and function of 5-HT₃Rs indicate that they belong to the Cys-loop family of ligand-gated ion

**ABBREVIATIONS:** 5-HT, 5-hydroxytryptamine; 5-HT₃R, 5-HT₃ receptor; AAS, anabolic androgenic steroid; ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer disease; BLA, basolateral subregion; CB₁R, cannabinoid type 1 receptor; CNS, central nervous system; CRH, corticotropin-releasing hormone; CS, conditional stimulus; DA, dopamine; DRN, dorsal raphe nucleus; FST, forced swim test; HPA, hypothalamic-pituitary-adrenal; IBS, irritable bowel syndrome; IL, interleukin; LC, locus coeruleus; LPS, lipopolysaccharide; m-CPBG, meta-chlorophenyl-biguanide; MAPK, mitogen-activated protein kinase; MDL 72222, C15H18Cl3NO2; NAc, nucleus accumbens; nAChR, nicotinic acetylcholine receptor; NE, norepinephrine; NO, nitric oxide; OCD, obsessive-compulsive disorder; PD, Parkinson disease; PFC, prefrontal cortex; PPAR, peroxisome proliferator–activated receptor; PTSD, post-traumatic stress disorder; PTZ, pentylenetetrazol; RG3487, C15H19ClN4O; SNP, single nucleotide polymorphism; SR57227, C10H15Cl3N3; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; US, unconditional stimulus; VTA, ventral tegmental area.
channels, which also includes nicotinic acetylcholine receptors (nAChRs) and GABA<sub>A</sub> receptors. 5-HT<sub>3</sub>R is composed of five subunits surrounding a central ion-conducting pore that is permeable to sodium, potassium, and calcium ions (Faerber et al., 2007). Each subunit comprises extracellular, transmembrane, and intracellular domains. The extracellular domain contains the binding site for ligands such as agonists and competitive antagonists and constitutes the major therapeutic target within 5-HT<sub>3</sub>R. Thus far, genes for five 5-HT<sub>3</sub> subunits have been identified (A–E), which encode proteins that bear differences in the N-terminal and transmembrane regions. Despite what was assumed earlier, all 5-HT<sub>3</sub> subunits are expressed in the central nervous system (CNS). Inclusion of A subunits renders the receptors functional, giving rise to homomeric 5-HT<sub>3A</sub> or heteromeric 5-HT<sub>3</sub>Rs expressed on neurons (Miyake et al., 1995; Fiebich et al., 2004b; Thompson and Lummis, 2007; Thompson et al., 2010). Although heteromeric receptors containing 5-HT<sub>3C</sub>, 5-HT<sub>3D</sub>, or 5-HT<sub>3E</sub> subunits possess 5-HT–induced responses and biophysical properties similar to those of homomeric 5-HT<sub>3A</sub> receptors, little is known about their pharmacology (Niesler et al., 2007). Heteromeric 5-HT<sub>3AB</sub> receptors, on the other hand, show disparate characteristics. These compositions differ greatly in single channel conductance, calcium permeability, 5-HT concentration–response curves, desensitization rate, and current–voltage relationships (Davies et al., 1999; Kelley et al., 2003b; Peters et al., 2010; Thompson and Lummis, 2013).

5-HT<sub>3</sub>Rs are found in both the CNS and peripheral nervous system. They are expressed in many brain regions, including the hippocampus, entorhinal cortex, frontal cortex, cingulate cortex, amygdala, nucleus accumbens (NAc), substantia nigra, and ventral tegmental area (VTA), with the highest densities in the area postrema and the nucleus tractus solitaries, regions responsible for the vomiting reflex (Thompson and Lummis, 2006). Activation of presynaptic 5-HT<sub>3</sub>Rs causes a rapid rise in cytosolic calcium concentration by inducing calcium influx, thereby modulating the release of a long list of neurotransmitters and neuropeptides. Postsynaptic 5-HT<sub>3</sub>Rs are associated with fast excitatory sodium and potassium-dependent depolarization (Krzywkowski et al., 2008). Moreover, depending on the type of neurons studied, presynaptic and postsynaptic 5-HT<sub>3</sub>Rs differ in cellular localization across different brain areas (Thompson and Lummis, 2006).

When the distribution of HTR3A and HTR3B in the human brain was interrogated by means of mRNA analyses, both subunits were detected in all brain regions studied except the cerebellum. However, the A/B subunit ratio varied drastically across different brain regions. Intriguingly, HTR3B has the highest expression in many brain areas with relevance to psychiatric disorders, namely the brain stem, amygdala, and frontal cortex (Hammer et al., 2012), raising the possibility of a role for altered stoichiometry/function of 5-HT<sub>3</sub>R subunits in the pathomechanism of such afflictions. Apart from the CNS, the 5-HT<sub>3A</sub> subunit has been detected in nonneural cells such as T cells, monocytes, synovial tissue, and primary chondrocytes (Thompson and Lummis, 2013).

The multiple possibilities in subunit combinations along with diverse patterns of tissue-specific distribution and pharmacological/biophysical properties make 5-HT<sub>3</sub>Rs an attractive candidate for novel therapeutic targets (Thompson and Lummis, 2013).

### A. 5-HT<sub>3</sub> Receptor Agonists

Apart from serotonin as the endogenous amine agonist, various 5-HT<sub>3</sub>R agonists have been synthesized as pharmacological tools. A handful of other compounds have been found to activate these receptors (Table 1).

One of the most selective and potent agonists is meta-chlorophenyl-biguanide (m-CPBG). The agonists at 5-HT<sub>3</sub>R do not usually possess any important clinical indication, as they are extremely emetogenic and can lead to hyperalgesia (Kilpatrick et al., 1990). Varenicline, a partial agonist at nAChR that has been approved for smoking cessation, is also a partial agonist at 5-HT<sub>3</sub>R (Rollema et al., 2007). This property could be responsible for nausea, the most common adverse effect reported with varenicline in smoking cessation trials (Neve et al., 1991; Gonzales et al., 2006). The application of 5-HT<sub>3</sub>R agonists is thus mostly confined to experimental studies to decipher the unknown roles of these receptors in physiologic and pathologic conditions (Thompson, 2013).

#### 1. 5-HT<sub>3</sub> Receptor Competitive Antagonists

To date, nausea and vomiting are the most prescribed therapeutic indications of competitive 5-HT<sub>3</sub>R antagonists (the setron family). Setrons have revolutionized oncology by potently treating chemotherapy-induced nausea and vomiting. The use of alosetron in diarrhea-predominant irritable bowel syndrome (IBS) has been hampered by its life-threatening adverse effect of ischemic colitis in a subset of patients. Recent investigations have focused more on palonosetron, a second-generation 5-HT<sub>3</sub>R antagonist. Palonosetron is highly selective for 5-HT<sub>3</sub>R and possesses greater affinity, a longer plasma half-life, and improved efficacy in preventing chemotherapy-induced nausea and vomiting compared with first-generation setrons (Rojas et al., 2010; Thompson, 2013). A detailed list of competitive antagonists is shown in Table 1.

#### 2. 5-HT<sub>3</sub> Receptor Noncompetitive Antagonists

Noncompetitive antagonists bind to locations other than the orthosteric binding site and therefore their action cannot be overcome by the addition of an agonist. The number of these antagonists is increasing dramatically. Noncompetitive antagonists at 5-HT<sub>3</sub>Rs can generally be classified into plant-derived and synthesized
### TABLE 1
Compounds modulating 5-HT₃Rs

<table>
<thead>
<tr>
<th>Drug or Compound</th>
<th>Species</th>
<th>Receptor Subtype</th>
<th>$K_i$ or $IC_{50}$</th>
<th>Main Effect, Application, or Therapeutic Use</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1E-115&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>5-HT₃A</td>
<td>1.2 µM</td>
<td></td>
<td>Hussey et al., 1994</td>
</tr>
<tr>
<td>SCG (mouse)</td>
<td>—</td>
<td>5-HT₃A</td>
<td>1.2 µM</td>
<td></td>
<td>Hussy et al., 1994</td>
</tr>
<tr>
<td>NG108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>13 µM</td>
<td></td>
<td>Hope et al., 1994</td>
</tr>
<tr>
<td>Human&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>123 nM</td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>Rat</td>
<td></td>
<td>5-HT₃A</td>
<td>219 nM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>2-Methyl-5-HT</td>
<td>N1E-115&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>11 µM</td>
<td>Derivative of serotonin</td>
<td>Hussey et al., 1994</td>
</tr>
<tr>
<td>SCG (mouse)</td>
<td>—</td>
<td>5-HT₃A</td>
<td>11.8 µM</td>
<td></td>
<td>Hussy et al., 1994</td>
</tr>
<tr>
<td>Human&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>219 nM</td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>Human&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>219 nM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>m-CPBG</td>
<td>Mouse&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>400 nM</td>
<td>Pharmacological tool</td>
<td>Downie et al., 1994</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>19.5 nM</td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>480 nM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>1.5 nM</td>
<td></td>
<td>Kilpatrick et al., 1990</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>4.77 nM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Phenylbiguanide</td>
<td>Mouse&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>18 µM</td>
<td>Pharmacological tool</td>
<td>Downie et al., 1994</td>
</tr>
<tr>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>5-HT₃A</td>
<td>1.2 µM</td>
<td></td>
<td>Dukat et al., 1996</td>
</tr>
<tr>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>5-HT₃A</td>
<td>1.8 µM</td>
<td></td>
<td>Downie et al., 1995</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>2.4 µM</td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>10.1 µM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>135 nM</td>
<td></td>
<td>Dubin et al., 1999</td>
</tr>
<tr>
<td>Varenicline</td>
<td>Human&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5.9 µM</td>
<td>Used for smoking cessation</td>
<td>Lummis et al., 2011</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>0.27 µM</td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>Mouse&lt;sup&gt;g&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>18.3 µM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>4.9 µM</td>
<td></td>
<td>Downie et al., 1994</td>
</tr>
<tr>
<td>m-CPP</td>
<td>Mouse&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>400 nM</td>
<td>Nonselective agonist with psychostimulant</td>
<td>Downie et al., 1994</td>
</tr>
<tr>
<td>Human&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>19.5 nM</td>
<td>Piperazine analog with antidepressant and oxytocic properties</td>
<td>Dubin et al., 1999</td>
</tr>
<tr>
<td>Human&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>19.5 nM</td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>Rat</td>
<td></td>
<td>5-HT₃A</td>
<td>4.77 nM</td>
<td></td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Quipazine</td>
<td>Human&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>27 nM</td>
<td>Piperazine analog with antidepressant and oxytocic properties</td>
<td>Dubin et al., 1999</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Human&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>135 µM</td>
<td>Neurotransmitter</td>
<td>Dubin et al., 1999</td>
</tr>
<tr>
<td>2-Chlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>62 nM</td>
<td></td>
<td>Dukat et al., 1996</td>
</tr>
<tr>
<td>3-Chlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>17 nM</td>
<td></td>
<td>Dukat et al., 1996</td>
</tr>
<tr>
<td>4-Chlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>200 nM</td>
<td></td>
<td>Dukat et al., 1996</td>
</tr>
<tr>
<td>2-Naphthylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>12 nM</td>
<td></td>
<td>Dukat et al., 1996</td>
</tr>
<tr>
<td>3,4-Dichlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>40 nM</td>
<td></td>
<td>Dukat et al., 1996</td>
</tr>
<tr>
<td>3,4,5-Trichlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>3.1 nM</td>
<td></td>
<td>Glennon et al., 2003</td>
</tr>
<tr>
<td>3,4-Dichlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>0.7 nM</td>
<td></td>
<td>Glennon et al., 2003</td>
</tr>
<tr>
<td>3,4-Dichlorophenylbiguanide</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>3.1 nM</td>
<td></td>
<td>Glennon et al., 2003</td>
</tr>
<tr>
<td>N-Methylquipazine dimaleate</td>
<td>Rat</td>
<td>—</td>
<td>4.7 nM</td>
<td></td>
<td>Glennon et al., 1989</td>
</tr>
<tr>
<td>RS 56812 hydrochloride</td>
<td>Rat</td>
<td>—</td>
<td>4.7 nM</td>
<td></td>
<td>Clark et al., 1995</td>
</tr>
<tr>
<td>SR 57272A</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>2.8 nM</td>
<td>Pharmacological tool</td>
<td>Bachy et al., 1993</td>
</tr>
<tr>
<td>Competitive antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granisetron</td>
<td>Mouse&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>0.14 nM</td>
<td>Antiemetic used for CINV</td>
<td>Downie et al., 1994</td>
</tr>
<tr>
<td>Human&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5-HT₃A</td>
<td>5-HT₃A</td>
<td>1.44 nM</td>
<td>Antiemetic used for CINV</td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>N1E-115&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>5-HT₃A</td>
<td>0.23 nM</td>
<td>Antiemetic used for CINV</td>
<td>Lummis et al., 1993</td>
</tr>
<tr>
<td>Rat</td>
<td></td>
<td>5-HT₃A</td>
<td>5.13 nM</td>
<td>Antiemetic used for CINV</td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>NG 108-15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>—</td>
<td>3.85 nM</td>
<td>Antiemetic used for CINV</td>
<td>Downie et al., 1995</td>
</tr>
<tr>
<td>Rat</td>
<td></td>
<td>—</td>
<td>4.9 nM</td>
<td>Antiemetic used for CINV</td>
<td>Steward et al., 1995</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug or Compound</th>
<th>Species</th>
<th>Receptor Subtype</th>
<th>Ki, nM</th>
<th>Main Effect, Application, or Therapeutic Use</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron</td>
<td>Rabbit</td>
<td>—</td>
<td>0.046</td>
<td>Antiemetic used for CINV</td>
<td>Peters et al., 1993</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Mouse</td>
<td>d 5-HT3A</td>
<td>0.44</td>
<td>Antiemetic used for CINV</td>
<td>Gill et al., 1995</td>
</tr>
<tr>
<td>Human</td>
<td>c 5-HT3A</td>
<td>4.9</td>
<td></td>
<td></td>
<td>Hope et al., 1996</td>
</tr>
<tr>
<td>N1E-115</td>
<td>—</td>
<td>a</td>
<td>7.4</td>
<td>Antiemetic, also used for IBS</td>
<td>Lummis et al., 1990</td>
</tr>
<tr>
<td>—</td>
<td>Mouse (NCB-20 cells)</td>
<td>—</td>
<td>0.25</td>
<td>Used for IBS-D</td>
<td>Lambert et al., 1989</td>
</tr>
<tr>
<td>Rabbit</td>
<td>—</td>
<td>—</td>
<td>0.057</td>
<td>Antiemetic</td>
<td>Peters et al., 1993</td>
</tr>
<tr>
<td>Dolasetron</td>
<td>NG 108-15</td>
<td>b</td>
<td>20.03</td>
<td>Antiemetic</td>
<td>Boeijinga et al., 1992</td>
</tr>
<tr>
<td>Azasetron</td>
<td>Rat</td>
<td>—</td>
<td>2.9</td>
<td>Antiemetic</td>
<td>Sato et al., 1992</td>
</tr>
<tr>
<td>Ramosetron</td>
<td>Human</td>
<td>c</td>
<td>0.091</td>
<td>Antiemetic, also used for IBS</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>0.22</td>
<td>Antiemetic</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>Alosetron</td>
<td>Guinea pig</td>
<td>—</td>
<td>50</td>
<td>Used for IBS-D</td>
<td>Zhai et al., 1999</td>
</tr>
<tr>
<td>Human</td>
<td>c</td>
<td>—</td>
<td>0.29</td>
<td>Antiemetic</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>0.71</td>
<td>Antiemetic</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>Cilansetron</td>
<td>Human</td>
<td>c</td>
<td>0.56</td>
<td>Used for IBS-D</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>0.64</td>
<td>Antiemetic</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>Palonosetron</td>
<td>Guinea pig</td>
<td>—</td>
<td>5.01</td>
<td>Antiemetic, also used for IBS</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>1.62</td>
<td>Antiemetic</td>
<td>Hirata et al., 2007</td>
</tr>
<tr>
<td>Indisetron</td>
<td>Rat</td>
<td>—</td>
<td>1.82</td>
<td>Antiemetic, also used for IBS</td>
<td>Taniguchi, 2004</td>
</tr>
<tr>
<td>Bemesetron (MDL-72222)</td>
<td>N1E-115</td>
<td>a</td>
<td>16</td>
<td>Antiemetic</td>
<td>Lummis et al., 1990</td>
</tr>
<tr>
<td>SCG (mouse)</td>
<td>—</td>
<td>—</td>
<td>5</td>
<td>Antiemetic</td>
<td>Hussy et al., 1994</td>
</tr>
<tr>
<td>NG108-15</td>
<td>—</td>
<td>—</td>
<td>3.5</td>
<td>Antiemetic, also used for IBS</td>
<td>Hussy et al., 1994</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>30.2</td>
<td>Antiemetic, also used for IBS</td>
<td>Hussy et al., 1994</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>2.9</td>
<td>Antiemetic, also used for IBS</td>
<td>Eisensamer et al., 2003</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>2.9</td>
<td>Antiemetic, also used for IBS</td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Zacopride</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>0.38</td>
<td>Antiemetic, also used for IBS</td>
<td>Nagakura et al., 1999</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>0.95</td>
<td>Antiemetic, also used for IBS</td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>—</td>
<td>Rat</td>
<td>—</td>
<td>10.9</td>
<td>Antiemetic, also used for IBS</td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Renzapride</td>
<td>Rat</td>
<td>—</td>
<td>67.6</td>
<td>Antiemetic, also used for IBS</td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Clozapine</td>
<td>Rat</td>
<td>—</td>
<td>269</td>
<td>Antiemetic, also used for IBS</td>
<td>Steward et al., 1995</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>24.3</td>
<td>Antiemetic, also used for IBS</td>
<td>Thompson and Lummis, 2008</td>
</tr>
<tr>
<td>Mefloquine</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>0.66</td>
<td>Antiemetic, also used for IBS</td>
<td>Thompson and Lummis, 2008</td>
</tr>
<tr>
<td>Quinine</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>1.06</td>
<td>Antiemetic, also used for IBS</td>
<td>Thompson and Lummis, 2008</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>N1E-115</td>
<td>a 5-HT3A</td>
<td>5.5</td>
<td>Antiemetic, also used for IBS</td>
<td>Gunthorpe and Lummis, 1999</td>
</tr>
<tr>
<td>(+)-Verapamil</td>
<td>N1E-115</td>
<td>a 5-HT3A</td>
<td>2.6</td>
<td>Antiemetic, also used for IBS</td>
<td>Hargreaves et al., 1996</td>
</tr>
<tr>
<td>(−)-Verapamil</td>
<td>N1E-115</td>
<td>a 5-HT3A</td>
<td>13.1</td>
<td>Antiemetic, also used for IBS</td>
<td>Hargreaves et al., 1996</td>
</tr>
<tr>
<td>Cannabidiol</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>0.6</td>
<td>Antiemetic, also used for IBS</td>
<td>Yang et al., 2010</td>
</tr>
<tr>
<td>Poria cocos triterpenoids</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>3</td>
<td>Antiemetic, also used for IBS</td>
<td>Lee et al., 2009</td>
</tr>
<tr>
<td>Boldine</td>
<td>Human</td>
<td>c 5-HT3A</td>
<td>5.5</td>
<td>Antiemetic, also used for IBS</td>
<td>Walstab et al., 2014</td>
</tr>
<tr>
<td>Scopolamine</td>
<td>Human</td>
<td>c 5-HT3A</td>
<td>2.09</td>
<td>Antiemetic, also used for IBS</td>
<td>Baptista-Hon et al., 2012</td>
</tr>
<tr>
<td>Atropine</td>
<td>Human</td>
<td>c 5-HT3A</td>
<td>1.74</td>
<td>Antiemetic, also used for IBS</td>
<td>Lecher and Thompson, 2016</td>
</tr>
<tr>
<td>Quercetin</td>
<td>Human</td>
<td>d 5-HT3A</td>
<td>64.7</td>
<td>Antiemetic, also used for IBS</td>
<td>Lee et al., 2009</td>
</tr>
<tr>
<td>Drug or Compound</td>
<td>Species</td>
<td>Receptor Subtype</td>
<td>$K_i$, IC$<em>{50}$, or EC$</em>{50}$</td>
<td>Main Effect, Application, or Therapeutic Use</td>
<td>Reference</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------</td>
<td>-----------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td><strong>Noncompetitive antagonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alisol extract</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>1.7–35 μM</td>
<td>Traditional medicine with diuretic, hypolipemic, antiatherosclerotic, and antihepatitis B virus properties</td>
<td>Lee et al., 2010</td>
</tr>
<tr>
<td>Anandamide</td>
<td>Human$^c$</td>
<td>5-HT$_{3A}$</td>
<td>129.6 nM</td>
<td>Endocannabinoid</td>
<td>Barann et al., 2002</td>
</tr>
<tr>
<td>Δ9-THC</td>
<td>Human$^c$</td>
<td>5-HT$_{3A}$</td>
<td>38.4 nM</td>
<td>Main psychoactive component of cannabis</td>
<td>Barann et al., 2002</td>
</tr>
<tr>
<td>WIN55,212-2</td>
<td>Human$^c$</td>
<td>5-HT$_{3A}$</td>
<td>103.5 nM</td>
<td>Synthetic, nonselective cannabinoid</td>
<td>Barann et al., 2002</td>
</tr>
<tr>
<td>Bilobalide</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>468 μM</td>
<td>Noncompetitive antagonist of GABA and glycine receptors</td>
<td>Thompson et al., 2011a</td>
</tr>
<tr>
<td>Ginkgolide B</td>
<td>Human$^d$</td>
<td>5-HT$_{3AB}$</td>
<td>3100 μM</td>
<td></td>
<td>Thompson et al., 2011a</td>
</tr>
<tr>
<td>Piperoxetin</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>11 μM</td>
<td></td>
<td>Thompson et al., 2011a</td>
</tr>
<tr>
<td>Picrotoxin</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>62 μM</td>
<td></td>
<td>Thompson et al., 2011a</td>
</tr>
<tr>
<td>Citral</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>41.2 μM</td>
<td>GABA$_A$ receptor antagonist</td>
<td>Das and Dillon, 2005</td>
</tr>
<tr>
<td>Linalool</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>141 μM</td>
<td>Terpenoid used as flavoring agent</td>
<td>Jarvis et al., 2016</td>
</tr>
<tr>
<td>Eucalyptol</td>
<td>Human$^d$</td>
<td>5-HT$_{3A}$</td>
<td>258 μM</td>
<td>Monoterpene from mentha used as flavoring agent</td>
<td>Jarvis et al., 2016</td>
</tr>
<tr>
<td>(−)-Menthol</td>
<td>Human$^c$</td>
<td>5-HT$_{3A}$</td>
<td>179.41 μM</td>
<td>Monoterpene from mentha used as flavoring agent</td>
<td>Walstab et al., 2014</td>
</tr>
<tr>
<td>Ginger extract</td>
<td>Human$^c$</td>
<td>5-HT$_{3A}$</td>
<td>74.9 nM</td>
<td>Traditional medicine used for spa</td>
<td>Walstab et al., 2013</td>
</tr>
</tbody>
</table>

Dashes indicate not identified or not applicable. CINV, chemotherapy-induced nausea and vomiting; IBS-D, diarrhea dominant IBS; m-CPP, meta-chlorophenylpiperazine; SCG, superior cervical ganglion.

$^a$Mouse neuroblastoma cells.
$^b$Mouse neuroblastoma × rat glioma hybrid cells.
$^c$Expressed in human embryonic kidney 293 cells.
$^d$Expressed in *Xenopus laevis* oocytes.
antagonists (Table 1). Cannabinoids (tetrahydrocannabinol), quinine, ginkgolides, resveratrol, ginseng, and liquorice are important examples of the former class, whereas antimalarial compounds (quinine and mefloquine) and diltiazem belong to the latter (Thompson et al., 2007, 2011a,b; Thompson and Lummis, 2008; Walstab et al., 2010). Intriguingly, 5-HT_3R antagonists and cannabinoids share several pharmacological properties such as analgesic, anti-inflammatory, and antiemetic effects. These common properties imply that 5-HT_3Rs can be closely involved in various pharmacological aspects of cannabinoids, and this dimension is of relevance for designing cannabinoid derivatives with fewer psychoactive effects (Rahimian et al., 2011b).

Steroids are also noncompetitive inhibitors of 5-HT_3R at pharmacological concentrations (Walstab et al., 2010; Davies, 2011). Generally, steroid-induced response is not rapid because steroids target gene-response elements downstream of activating their cytoplasmic receptors. The clinical importance of 5-HT_3R antagonism by steroids is that it may justify some of the rapid actions seen with steroids (sex hormones and glucocorticoids) such as antiemetic and analgesic properties.

Since 5-HT_3R is a ligand-gated cation channel, the response triggered by its modulation is fast. Noncompetitive antagonists have differential potencies at 5-HT_3A and 5-HT_3AB receptors. This characteristic makes them suitable experimental tools for distinguishing 5-HT_3R subtypes in tissues. Because of their off-target effects and in some cases their low potency, however, the importance and clinical potential of noncompetitive antagonists is still unknown (Thompson, 2013).

### C. 5-HT_3 Receptor Allosteric Modulators

Allosteric modulators of 5-HT_3Rs can be categorized as positive and negative modulators (Table 1). The first class facilitates channel opening, whereas the second class increases the energy barrier for gating and reduces the probability of channel opening (Thompson, 2013). A number of compounds have been shown to modulate 5-HT_3R, including general anesthetics, local anesthetics, steroids, antidepressants, and antipsychotics (Fan, 1994; Davies, 2011). This can be of translational relevance, as identification of novel targets for antidepressants and antipsychotics is crucial to minimizing the adverse effects of these widely prescribed drugs and opens avenues for the development of ligands with higher efficacies. This topic is discussed in detail in sections V.A and V.C.

### D. 5-HT_3 Receptor Ligands and Cholinergic System Modulation

1. **Dual 5-HT_3 Receptor Antagonist/Cholinesterase Inhibitors.** An analog of tacrine, an acetylcholinesterase (AChE) inhibitor, has been synthesized and demonstrates a nanomolar affinity for both 5-HT_3R and human AChE, whereas its potency in inhibiting butryrylcholinesterase is 10-fold lower. To this end, tacrine was fused with a spacer to an optimized 5-HT_3R antagonist. Hypothetically, such compounds might act to enhance acetylcholine (ACh) bioavailability through AChE inhibition, which is progressively diminished in the Alzheimer disease (AD)—inflicted brain and to interfere with the neurodegenerative events underpinning the disorder by antagonizing 5-HT_3Rs (Cappelli et al., 2005). However, tacrine therapy is associated with a very high rate of serum aminotransferase elevation over the course of therapy and with several instances of clinically conspicuous, acute liver injury (Alfirevic et al., 2007). Therefore, for a more translational approach, other cholinesterase inhibitors with safer profiles should replace tacrine.

2. **Dual 5-HT_3 Receptor Antagonists/Nicotinic Receptor Agonists.** RG3487 (C15H19ClN4O), a 5-HT_3R antagonist with α7 nAChR partial agonistic activity, significantly improved cognitive performance in rats (Rezvani et al., 2009). This ligand was later shown to enhance dopamine (DA) and ACh release in the medial prefrontal cortex (PFC) and hippocampus but not the NAc. The effect on both DA and ACh was dose dependent, with the former relying on α7 nAChR stimulation whereas the latter was mediated by 5-HT_3R antagonism (Huang et al., 2014). By targeting different receptors, this dual-acting compound can offer additional or synergistic benefits in debilitating diseases with a progressive nature such as AD and Parkinson disease (PD). Such multimodal action could provide high effectiveness for treating or delaying the progression of neurodegenerative disorders. Therefore, these pharmacotherapeutics can also serve as a scaffold to develop new agents that target both inflammation and neurodegenerative events.

### III. Biologic Effects of 5-HT_3 Receptor Antagonists, a Final Remark

In addition to an antagonistic action on their classic target 5-HT_3R, recent investigation associates setrons with other surface and intracellular molecules. Studies show that a number of protective actions of some setrons may not be merely explained through interaction with their conventional site of action. Indeed, important signaling molecules such as mitogen-activated protein kinase (MAPK) (Liu et al., 2012, 2016), calcineurin (Vega Lde et al., 2005; Rahimian et al., 2011b, 2013b; Dyrhfeld-Johnsen, 2016), and α7 nAChRs (Macor et al., 2001; Ishikawa et al., 2011) are affected by 5-HT_3R antagonists. Since many of these new targets are implicated in neurologic and neuropsychiatric diseases with unmet therapeutic needs, addressing them from various fronts by means of 5-HT_3R antagonists is tantalizing. Indeed, the concept of employing selective pharmacotherapeutics has been challenged by the fact that the complex nature of these diseases requires a
multifaceted therapy strategy. Such an approach can be achieved by 5-HT$_3$R antagonists.

Among the various classes of 5-HT$_3$R ligands, only sertrons have a place in pharmacotherapy, whereas other ligands merely serve as experimental tools. In the following sections, we provide an overview of these various pharmacological actions of 5-HT$_3$R antagonists in neurologic and neuropsychiatric disorders.

IV. 5-HT$_3$ Receptor Antagonists in Neurologic Disorders

A. Seizure

It is becoming increasingly evident that serotonergic neurotransmission plays a major role in chemically and electrically evoked seizures. 5-HT$_3$Rs are among the 5-HT receptor subtypes with an established contribution to epileptogenesis and/or propagation (Pytka et al., 2017; Zhao et al., 2018). It is generally accepted that agents that enhance extracellular 5-HT content inhibit both focal and generalized seizures. Examples include 5-HT precursor 5-hydroxytryptophan and selective serotonin reuptake inhibitors (SSRIs). In contrast, agents that lower brain 5-HT levels decrease the seizure threshold. In line with this notion, many antiepileptics elevate endogenous extrasynaptic 5-HT levels (Bagdy et al., 2007).

However, both anticonvulsant and proconvulsant properties have been reported with 5-HT$_3$R antagonists (Tables 2 and 3). This implies that their pharmacological effects on seizure threshold depend on various factors, including dose-related sensitivity of physiologic pathways, differences in ligand pharmacodynamics and pharmacokinetics, and dissimilarity of experimental seizure models used (Mishra and Goel, 2016). Dissecting these opposing properties of 5-HT$_3$R antagonists is of pharmacological significance both in terms of drug development and management of neurologic adverse effects of 5-HT$_3$R antagonists.

Seizures occur in 13% of all patients with cancer, comprising approximately 5% of neurologic manifestations (Clouston et al., 1992). The occurrence of seizures in patients with cancer might stem from a variety of causes such as cytotoxic chemotherapy, brain parenchymal and meningeal metastasis, and toxic–metabolic encephalopathy. The proconvulsant potential of 5-HT$_3$R antagonists should be considered in chemotherapy regimens. Therefore, caution is advised when coadministering 5-HT$_3$R antagonists with chemotherapeutic agents (e.g., cisplatin, methotrexate, chlorambucil, and busulphan) that can potentiate the development of convulsions (Singh et al., 2007), especially in a subset of patients prone to seizure such as those suffering from brain tumors (Gharedaghi et al., 2014).

The use of 5-HT$_3$Rs agonists as antiepileptic agents in humans is not a therapeutic option, considering the presence of these receptors on afferent vagal nerve fibers and neurons in the chemoreceptor trigger zone. Therefore, 5-HT$_3$R stimulation can potentially cause bradycardia, nausea, and vomiting (Jeggo et al., 2005; Tuerke et al., 2012). Regarding the established place of 5-HT$_3$R antagonists in chemotherapy regimens, it is crucial to elucidate the mechanisms by which they modulate the seizure threshold.

A number of studies have reported generalized tonic-clonic seizures with sertrons in children and adults (Sargent et al., 1993; Sharma and Raina, 2001; George et al., 2008; Singh et al., 2009; Patel et al., 2011). A study showed that SR57227 (C10H15Cl2N3) increases, but granisetron decreases, the threshold for pentylenetetrazol (PTZ)–induced clonic seizures in mice (Gholipour et al., 2010). In the same model, m-CBPG potentiated the additive anticonvulsant properties of morphine and citalopram, whereas tropisetron abolished such an additive effect, pointing to the 5-HT$_3$R dependence of the effect (Bahremand et al., 2011; Payandemehr et al., 2012; Gharedaghi et al., 2014). In line with these findings, MDL 72222 (C15H18Cl3N2O2) aggravates seizures evoked by ethanol withdrawal in mice (Grant et al., 1994) (Tables 1 and 2).

5-HT$_3$Rs are expressed in virtually all of the networks engaged in epileptogenesis, mainly on GABAergic interneurons in the amygdala, hippocampus, and neocortex. Their activation by 5-HT or selective agonist m-CBPG eventually leads to hyperpolarization of neurons in these brain regions (Ropert and Guy, 1991; Hornung and Celio, 1992; Tecott et al., 1993; Kawa, 1994; Staubli and Xu, 1995; McMahon and Kauer, 1997; Katsurabayashi et al., 2003; Brady et al., 2007). Conversely, 5-HT$_3$Rs antagonists reduce the firing rate of hippocampal inhibitory interneurons, thereby increasing the discharge rate of pyramidal cells in this region (Reznic and Staubli, 1997). Based on these pieces of evidence, it is plausible that activation of brain inhibitory interneurons through 5-HT$_3$Rs stimulation plays an important role in the anticonvulsant effect of SSRIs and agonists at 5-HT$_3$Rs (Gholipour et al., 2010). Another explanation for the observed proconvulsant actions of 5-HT$_3$R antagonists (Table 2) is the ability found with a subset of them, including tropisetron, to inhibit calcineurin activity (Rahimian et al., 2011b). The calcium-activated serine/threonine phosphatase calcineurin is highly abundant in the brain, accounting for more than 1% of the total protein, and regulates transcription and activity state of multiple signaling molecules (Klee et al., 1998; Rusnak and Mertz, 2000). Administration of classic calcineurin inhibitors such as cyclosporin A, as an immunosuppressant for graft rejection, induced seizure in a cohort of patients (Gleeson et al., 1998; Zakrzewski, 2003).

However, some studies reported a proconvulsive effect for 5-HT$_3$R stimulation. Ondansetron has been reported to exert anticonvulsant activity and potentiate the anticonvulsant effect of phenytoin in maximal electroshock-induced seizures in rats (Balakrishnan...
<table>
<thead>
<tr>
<th>Category</th>
<th>Compound, Dose, Route of Administration</th>
<th>Study Design</th>
<th>Effects</th>
<th>Proposed Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-HT&lt;sub&gt;3&lt;/sub&gt;R agonist</td>
<td>Bemesetron (MDL-72222) (0, 5.6, 10, and 17.0 mg/kg, i.p.)</td>
<td>Ethanol withdrawal-induced seizure in mice</td>
<td>Potentiates severity of seizures</td>
<td>Inhibits GABA-activated chloride channels</td>
<td>Grant et al., 1994</td>
</tr>
<tr>
<td></td>
<td>m-CPBG (40 μg, i.c.v.)</td>
<td>Kindling model of epilepsy in rats</td>
<td>Prolongs the duration of fully kindled seizures, facilitates the development of seizure</td>
<td>5-HT&lt;sub&gt;3&lt;/sub&gt;Rs activation mediates a fast excitatory postsynaptic potential in the amygdala</td>
<td>Wada et al., 1997</td>
</tr>
<tr>
<td>5-HT&lt;sub&gt;3&lt;/sub&gt;R antagonist</td>
<td>Granisetron (10 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Decreases seizure threshold</td>
<td>Blockade of 5-HT&lt;sub&gt;3&lt;/sub&gt;R-mediated cation conductance in GABAergic interneurons disinhibits excitatory postsynaptic neurons</td>
<td>Gholipour et al., 2010</td>
</tr>
<tr>
<td></td>
<td>Ondansetron (0.13 mg/kg, i.v.)</td>
<td>Case report in a child</td>
<td>Develops generalized tonic-clonic seizures, reduces blood glucose level to 10 mg/dl</td>
<td>Anticonvulsant effect of fluvoxamine, at least in part, depends on enhancement of hippocampal serotonergic transmission at 5-HT&lt;sub&gt;3&lt;/sub&gt;Rs</td>
<td>Patel et al., 2011</td>
</tr>
<tr>
<td></td>
<td>Ondansetron (2 mg/kg, i.p.)</td>
<td>PTZ-induced kindling model of epilepsy in mice</td>
<td>Partially reverses the anticonvulsant action and neuroprotective effect of fluvoxamine</td>
<td>Blockade of the 5-HT&lt;sub&gt;3&lt;/sub&gt;R as a calcium-conducting ion channel results in inhibition of early depolarization of inhibitory interneurons</td>
<td>Alhaj et al., 2015</td>
</tr>
<tr>
<td></td>
<td>Tropisetron (1 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Inhibits the anticonvulsant effect of citalopram</td>
<td>Estrogen and 5-HT&lt;sub&gt;3&lt;/sub&gt;Rs are involved in the anticonvulsant effect of genistein</td>
<td>Payandemehr et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Tropisetron (10 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Offsets the anticonvulsant effect of genistein</td>
<td>Anticonvulsive effect of citalopram is mediated at least in part through 5-HT&lt;sub&gt;3&lt;/sub&gt;Rs</td>
<td>Amiri Gheshlaghi et al., 2017</td>
</tr>
<tr>
<td></td>
<td>Tropisetron (0.25 and 2 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Inhibits the anticonvulsant properties of citalopram</td>
<td>—</td>
<td>Bahremand et al., 2011</td>
</tr>
</tbody>
</table>

Dashes indicate not identified or not applicable.
### TABLE 3
Anticonvulsant effects reported with 5-HT₃R ligands

<table>
<thead>
<tr>
<th>Category</th>
<th>Compound, Dose, Route of Administration</th>
<th>Study Design</th>
<th>Effects</th>
<th>Proposed Mechanisms</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-HT₃R agonists</td>
<td>m-CPBG (5 and 10 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Potentiates the anticonvulsant effect of low doses of citalopram</td>
<td>5-HT₃R activation increases firing of interneurons and subsequent GABA release</td>
<td>Payandemehr et al., 2012</td>
</tr>
<tr>
<td></td>
<td>m-CPBG (1 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Potentiates the anticonvulsant effect of genistein</td>
<td>5-HT₃R is involved in the anticonvulsant effect of genistein</td>
<td>Amiri Geshlaghi et al., 2017</td>
</tr>
<tr>
<td></td>
<td>SR 57227 (20–40 mg/kg, i.p.)</td>
<td>PTZ-induced seizure in mice</td>
<td>Anticonvulsant; prolongs seizure latency, reduces seizure score and mortality</td>
<td>5-HT₃R activation may result in GABA release in the hippocampus</td>
<td>Li et al., 2014</td>
</tr>
<tr>
<td></td>
<td>SR57227 (10 mg/kg, i.p.)</td>
<td>PTZ-induced seizure threshold in mice</td>
<td>Increases seizure threshold</td>
<td>5-HT₃R activation may result in GABA release</td>
<td>Gholipour et al., 2010</td>
</tr>
<tr>
<td>5-HT₃R antagonists</td>
<td>HBK-15 (20, 30, and 40 mg/kg, i.p.)</td>
<td>Maximal electroshock-induced seizure in mice</td>
<td>Increases the threshold for tonic seizures</td>
<td>Combined antagonistic action at 5-HT₁₂/5-HT₃/5-HT₇ receptors and voltage-dependent sodium channels</td>
<td>Pytka et al., 2017</td>
</tr>
<tr>
<td></td>
<td>Ondansetron (0.1, 0.5, and 1 mg/kg per day for 20 days, i.p.)</td>
<td>PTZ-induced kindling in mice</td>
<td>Reduction in seizure severity and associated memory deficit in a dose-dependent manner</td>
<td>Reduction in AChE activity and nitrite level in the cortex and hippocampus</td>
<td>Mishra and Goel, 2016</td>
</tr>
<tr>
<td></td>
<td>Ondansetron (0.1, 0.5, and 1 mg/kg per day, i.p.)</td>
<td>Increasing current electroshock seizure in mice</td>
<td>Single dose and chronic treatment enhance the seizure threshold, chronic treatment enhances cognitive performance</td>
<td>Change in the influx of cations, leading to the inhibition of neuronal depolarization</td>
<td>Jain et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Ondansetron (0.25–4 mg/kg, i.p.)</td>
<td>Maximal electroshock-induced seizure in rats</td>
<td>Decreases the duration of tonic seizures at low doses, attenuates phenytoin-induced cognitive dysfunction</td>
<td>Facilitation of cholinergic transmission in brain</td>
<td>Balakrishnan et al., 2000</td>
</tr>
<tr>
<td></td>
<td>Zacopride (1 mg/kg, i.p.)</td>
<td>Audiogenic seizure in DBA/2 mice</td>
<td>Increases seizure latency and decreases seizure severity</td>
<td>Alteration of brain 5-HT content, densities of 5-HT binding sites, and/or sensitivity to 5-HT receptor agonists</td>
<td>Semenova and Ticku, 1992</td>
</tr>
</tbody>
</table>

*1-[2-chloro-6-methylphenoxy]ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride.*
et al., 2000). In the amygdala kindling model of generalized seizures in rats, the 5-HT3 agonist m-CPBG lowered the seizure threshold (Wada et al., 1997). In line with these observations, granisetron shortened the duration of primary after discharges, thereby attenuating hippocampal partial seizures evoked by low-frequency electrical stimulation. Interestingly, the effect was dose specific; the dose of 1 mg/kg was anticonvulsant, whereas the 0.3- or 3-mg/kg doses were ineffective, yielding a U-shaped dose-response curve (Watanabe et al., 2000). These findings are in contrast with a report showing a proconvulsant effect of 10 mg/kg granisetron in a mouse model of PTZ-induced seizure (Gholipour et al., 2010). Chronic treatment with ondansetron and ondansetron were accompanied by a decrease in nitrite level and AChE activity in the cortex as well as in the hippocampus of kindled mice. To our knowledge, this is the first report implying that anti-inflammatory aspects of ondansetron may be involved in anticonvulsant actions of a 5-HT3R antagonist (Mishra and Goel, 2016). However, this apparent discrepancy might arise from a number of differences between the two studies, such as those in seizure models and animal species as well as in the doses of granisetron used, since bell-shaped dose-response curves have been described for select pharmacological actions of 5-HT3 antagonists.

As detailed above, 5-HT and selective 5-HT3 agonists can depolarize hippocampal interneurons, leading to hyperpolarization of CA1 pyramidal neurons. Adding to this, evidence suggests that stimulation of 5-HT3R gives rise to elevations in intraneuronal calcium concentrations, which subsequently activates neuronal nitric oxide (NO) synthase and triggers NO production (Reiser, 1990). Given the epileptogenic role of NO in some seizure models (Osonoe et al., 1994; Riazi et al., 2006), it is possible that 5-HT3 agonists simultaneously activate anticonvulsant and proconvulsant pathways in the hippocampus by stimulating inhibitory GABAergic interneurons and NO production, respectively. The ultimate outcome of 5-HT3 activation may therefore depend on several factors, including the species studied, the seizure model applied, the nature and dose of the drug used in the study, and so on. This hypothesis is supported by the results of an experiment showing that the anticonvulsant effect of SR57227 is facilitated by coadministration with the NO synthase inhibitor Nω-nitro-L-argininemethyl ester, whereas the NO precursor L-arginine potentiates the proconvulsant action of granisetron (Gholipour et al., 2010). Moreover, despite the selective expression of the majority of 5-HT3Rs on inhibitory interneurons in the hippocampal CA1 region, a subgroup of these receptors are also found on pyramidal cells, the stimulation of which can potentially activate pyramidal neurons and increase their excitability (Tecott et al., 1993).

B. Neurotoxicity Associated with Cancer Chemotherapy Drugs

Sensory-motor neuropathy is a severe side effect of vincristine experienced by patients with cancer, the recovery from which is usually incomplete (Authier et al., 2003). The pathomechanisms underpinning this adverse event, as shown by in vitro and in vivo studies, include damage to Schwann cells and dorsal root ganglion neurons as a result of laminin depletion in Schwann cells and neurite retraction in the dorsal root ganglion (Konings et al., 1994a,b), as well as disruption in the normal process of myelination (Djaldetti et al., 1996). Damaged Schwann cells release inflammatory cytokines (Shamash et al., 2002; Thacker et al., 2007) and chemokines that trigger the cascades of chemotaxis (Tofaris et al., 2002; White et al., 2005) and neuroinflammation, resulting in neuropathic pain in the form of hyperalgesia and allodynia. Interestingly, tropisetron pretreatment successfully attenuated vincristine-related nerve injury in rats, as evidenced by a reduction in behavioral and electrophysiological scores as well as diminution of pathologic and morphometric changes (Barzegar-Fallah et al., 2014). Granisetron at the same dosage, however, did not affect any of the assessed parameters and coadministration of the selective 5-HT3 agonist m-CPBG failed to offset the beneficial effects seen with tropisetron (Barzegar-Fallah et al., 2014). These observations suggest a 5-HT3R–independent mechanism of action for tropisetron. At the molecular level, elevation of intracellular calcium after nerve injury activates calcineurin, which in turn dephosphorylates nuclear factor of activated T cells, leading to its nuclear translocation. Consequently, several cytokines, including interleukin (IL)-2, IL-4, and tumor necrosis factor-α, are released and neuronal apoptosis ensues (Kantrow et al., 2000; Cai et al., 2013). Interestingly, tropisetron targets calcineurin as a central player in neuronal damage (Rahimian et al., 2011b) and, in keeping with the in vivo observation (Barzegar-Fallah et al., 2014), the inhibition of calcineurin phosphatase activity by tropisetron represents one plausible mode of action underlying the neuroprotective effects of this drug. Other mechanisms that potentially contribute to setrons’ protection against vincristine-associated neuropathy could include their ability to activate α7 nAChR (Swartz et al., 2013; Fakhfouri et al., 2015; Callahan et al., 2017), induction of the anti-inflammatory transcriptional factor nuclear factor erythroid 2–related factor 2 and its downstream molecules heme oxygenase and catalase (Khalifeh et al., 2015), as well as inhibition of p38 MAPK (Liu et al., 2012; Stratz et al., 2012). Interventions that exert these effects have been shown to attenuate vincristine-induced neuropathy (Shen et al., 2015).

The potential indication of 5-HT3R antagonists in counteracting chemotherapy-related neuropathy and
neurotoxicity is of high clinical relevance, as a seton is already part of the antiemetic regimen administered to patients with cancer who receive vincristine.

C. Central Component of Irritable Bowel Syndrome

IBS is a chronic heterogeneous gastrointestinal disorder with uncertain pathophysiology. Nevertheless, a high prevalence of psychiatric comorbidities (Fond et al., 2014) along with abnormalities reported from structural and functional imaging studies of patients with IBS increasingly point to dysfunction of brain–gut interactions as an etiological factor in IBS (Fichna and Storr, 2012; Bonaz, 2013; Tsang et al., 2016). Brain imaging studies suggest a possible alteration in the activation of subregions in the anterior cingulate cortex and emotional motor system, including the amygdala, ventromedial PFC, periaqueductal gray matter, and locus coeruleus (LC), during colorectal stimulation (Mertz et al., 2000; Naliboff et al., 2001, 2003).

The cognitive-behavioral model of IBS in animals also lends more credibility to the theory (Greenwood-Van Meerveld et al., 2001). In this model, a substantial link has been shown between the central pathways and regions mediating stress and anxiety, especially the amygdala, and mechanisms regulating colonic sensitivity and motility (Tyler et al., 2007). In this context, 5-HT is a pivotal monoamine involved in the brain–gut connection and is the best-described neurotransmitter in IBS pathology. Among the 5-HT receptors, 5-HT₃Rs stand out (Stasi et al., 2014). In fact, alosetron, a 5-HT₃R antagonist (Table 1), has shown effectiveness in treating diarrhea-predominant IBS. Alosetron alleviates abdominal discomfort and pain and improves stool consistency in both female and male patients, although its positive effects on sense of urgency, stool frequency, and bloating was only seen in female patients (Komoto and Miura, 2006). The mechanisms and sites underlying the therapeutic effect of alosetron in IBS are not completely understood. 5-HT₃Rs have been identified on peripheral terminals of spinal and vagal afferents, in the spinal cord, and at multiple supraspinal sites. The latter include nuclei in the dorsal pons (trigeminal motor nucleus), medulla (dorsal vagal complex), amygdala, hippocampus, ventral striatum, hypothalamus, and PFC (Fletcher and Barnes, 1999; Carrillo et al., 2010). In humans, the amygdala and dorsal vagal complex show the highest density of supraspinal 5-HT₃Rs (Mayer et al., 2002). Compared with placebo, 3 weeks of treatment with alosetron in nonconstipated patients with IBS decreased the activity of 5-HT₃R–containing regions of the emotional motor system, but not in areas activated by pain, in response to unanticipated, anticipated, and delivered aversive rectal stimuli. This was significantly correlated with improvement in gastrointestinal symptoms (Berman et al., 2002; Mayer et al., 2002).

Together, these results add grounds to the hypothesis that the CNS effects of 5-HT₃R antagonists play a significant role in counteracting the pathophysiology of this syndrome (Bonaz et al., 2002). Moreover, this class of drugs is also effective in alleviating CNS comorbidities of IBS such as anxiety and depression (discussed in corresponding subsections of section V.A and V.B).

D. Memory Disorders

Memory disorders can range from mild to severe, but they all result from some kind of neurologic damage of the brain, thus impeding the storage, retention, and recollection of memories. Memory disorders can be progressive, such as AD, or immediate, such as those resulting from brain injury. Cognitive deficit is also an integral part of schizophrenia clinical manifestations (Green et al., 2004). ACh is a crucial neurotransmitter that regulates cognitive performance, learning, and memory processes. During aging, cholinergic neurons of the basal forebrain complex undergo degenerative changes that lead to cholinergic hypofunction (Schliebs and Arendt, 2006). Basal forebrain cholinergic cell loss is also a core feature of AD (Liu et al., 2015) and PD dementia (Perry et al., 1985). In experimental studies, 5-HT₃R antagonism can reverse learning and memory deficits invoked by scopolamine or lesions to the cholinergic nucleus basalis of Meynert (Barnes et al., 1990; Chugh et al., 1991; Carli et al., 1997; Ohno and Watanabe, 1997). Antagonism at 5HT₃R also improved novel object recognition in aged monkeys (Arnsten et al., 1997) and aged rats (Callahan et al., 2017). As previously discussed, 5-HT₃Rs are highly expressed in the amygdala, hippocampus, and cortex, regions integral to memory processing (Gulyás et al., 1999; Thompson and Lummis, 2007; Walstab et al., 2010). The ability of the antagonists to enhance cholinergic neurotransmission in these regions (Maura et al., 1992; Diez-Ariza et al., 2002; Seyedabadi et al., 2014) can explain, in part, their procognitive actions.

Activation of α7 nAChR is another mode of action for memory-boosting properties of tropisetron (Callahan et al., 2017). This receptor has received considerable attention as a potential therapeutic target in AD and schizophrenia (for review, see Bertrand et al., 2015). The expression of α7 nAChR protein is markedly reduced in the AD cortex (Burghaus et al., 2000) and agonists of α7 nAChRs consistently improve various forms of cognitive performance in experimental studies (Levin et al., 1999; Boess et al., 2007) as well as in healthy volunteers (Kitagawa et al., 2003) and nonsmoking patients with schizophrenia (Olincy et al., 2006; Preskorn et al., 2014).

Tropisetron might provide an additional benefit in AD. In an animal model of AD (J20 mice), low doses of tropisetron increased the soluble APPα/APPβ-1-42 ratio, suggesting a favorable effect in ameliorating the AD pathology. This was accompanied by spatial and working
memory enhancement in symptomatic, preplaque phase, and late plaque phase. Intriguingly, tropisetron was superior to AD therapeutic drugs memantine and donepezil in both the cognitive aspect and amyloidogenic process (Spilman et al., 2014; Hashimoto, 2015). Tropisetron also protected against Aβ-induced neuroinflammation in vivo through the calcineurin pathway (Rahimian et al., 2013b). Much is still unknown about the exact role of 5-HT3R in dementia and AD. It has been reported that fibrillar Aβ is neurotoxic through blockade of α7 nAChRs, whereas oligomeric Aβ may oppositely activate α7 nAChRs, leading to stimulation of protective downstream signaling cascades (Khan et al., 2010; Lilja et al., 2011). However, we do not know whether such an interaction exists for other ligand-gated ion channels such as 5-HT3R and, if so, in which direction Aβ may affect the signaling of this receptor.

Another mediator that can account for serotonin-induced memory improvement is NO. NO is a crucial neuromodulator involved in memory through synaptic plasticity in various brain areas such as the hippocampus (Susswein et al., 2004; Javadi-Paydar et al., 2012), and the inhibition of NO synthesis impairs spatial memory in small rodents (Tanaka et al., 2009). Facilitation of the NO pathway has been reported to contribute to the ability of granisetron to improve spatial recognition memory in scopolamine-induced memory-impaired mice (Javadi-Paydar et al., 2012).

In addition to facilitation of cholinergic transmission and NO signaling, 5-HT3R antagonists can rescue cognition through various mechanisms, including anti-inflammatory effects (e.g., inhibition of nuclear factor-κB), induction of peroxisome proliferator-activated receptor γ (PPARγ) transcriptional activity (see section IV.F), and attenuation of calcium signaling (Rahimian et al., 2013b, 2016). Therefore, they hold great promise as a new therapeutic approach for memory impairments with complex etiopathology such as AD (for more details, see Fakhfouri et al., 2012, 2015). This potential is clinically relevant since U.S. Food and Drug Administration–approved memory-improving drugs such as cholinesterase inhibitors and memantine are not universally effective in patients with dementia (Raina et al., 2008) and AD (Schneider et al., 2011). Tropisetron has advanced into clinical trials for enhancing cognitive function in AD and schizophrenia (Bertrand et al., 2015).

E. Inner Ear Diseases

Dysfunction of the inner ear causes vertigo, hearing loss, and tinnitus in patients, leading to physical and functional impairment that is further associated with anxiety, social isolation, and cognitive decline (Jacob and Furman, 2001; Lin et al., 2011a; Bisdorff et al., 2013; Contrera et al., 2017; Kim et al., 2018). A number of pathologies, such as vestibular neuritis and sudden sensorineural hearing loss, have acute onset and lead to permanent impairments of inner ear function (Kuhn et al., 2011; Manzari et al., 2013) through degeneration of the sensory epithelium, primary nerves, and their synaptic connections, as documented in postmortem tissue samples from patients (Rauch, 2001; Merchant et al., 2005; Richard and Linthicum, 2012). In most cases, the etiology remains undetermined, although viral infections and cardiovascular causes have been speculated for both vestibular and cochlear sudden impairments (Strupp and Brandt, 2009; Chau et al., 2010; Linthicum et al., 2013; Manzari et al., 2013). After the acute episode of vestibular neuritis, up to approximately 50% of patients have permanent unilateral loss of function documented up to 10 years later (Strupp and Brandt, 2009), and more than 60% of patients suffer deficits with associated physical and functional handicaps 5 years after onset (Mandalà and Nuti, 2009). Sudden sensorineural hearing loss leads to permanent hearing impairment in 35%–68% of patients as measured with standard audiograms; even in the absence of hearing threshold deficits, patients can experience communication difficulties and tinnitus after an acute inner ear lesion (Schreiber et al., 2010; Spankovich et al., 2017). No registered pharmacological treatment currently exists for these acute-onset conditions, and current therapy primarily consists of off-label use of corticosteroids (Brandt et al., 2009; Walker, 2009; Stachler et al., 2012), although meta-analysis and systematic reviews have failed to demonstrate a significant treatment effect (Goudakos et al., 2010; Crane et al., 2015).

A small clinical pilot study conducted by Venail et al. (2012) demonstrated that patients with vestibular neuritis who received antiemetic treatment with ondansetron instead of the standard antiemetic metoclopramide recovered faster and exhibited reduced lasting vestibular dysfunction. Specifically, patients taking ondansetron demonstrated shorter time until first unassisted walk, reduced duration of hospitalization, and reduced vestibular deficits measured by caloric testing.

To further investigate the potential for a disease-modifying treatment effect of 5-HT3R antagonists in inner ear disease, an animal model of vestibular excitotoxic synaptic insult was implemented in female Long-Evans rats (Dyhrfjeld-Johnsen et al., 2013). To mimic the clinical situation as closely as possible, treatment with ondansetron was initiated after initial lesion induction. The preclinical study closely reproduced the clinical pilot study findings, demonstrating reduced functional impairment using behavioral scoring and reduced vestibular deficit as characterized by spontaneous nystagmus frequency measured with infrared video nystagmography equipment. Furthermore, the histologic comparison of tissue from ondansetron- and placebo-treated animals demonstrated preservation and accelerated recovery of afferent synapses between sensory hair cells and primary sensory neurons as the basis of the functional treatment effect. Loss of synaptic connections
by excitotoxically mediated insults in the inner ear has been demonstrated to lead to long-term degeneration of primary afferent neurons (Kujawa and Liberman, 2009; Lin et al., 2011b), reminiscent of postmortem histologic findings from patients (Rauch, 2001; Merchant et al., 2005; Richard and Linthicum, 2012). Further experiments demonstrated that not only ondansetron but also other calcineurin-inhibiting 5-HT3 antagonists such as tropisetron and azasetron effectively protected against kainate-induced synaptic loss in this animal model.

Subsequently, a number of 5-HT3 antagonists were tested at equimolar daily doses in a rat model of sudden sensorineural hearing loss induced by acute acoustic trauma, one of the few well established etiologies of this condition (Dyhrfjeld-Johnsen, 2016). This model involves not only excitotoxic decoupling of afferent synapses as in the vestibular unilateral lesion model but also loss of sensory hair cells through oxidative stress and apoptosis induced by acoustic overstimulation (Yamashita et al., 2004; Yang et al., 2004; Parham and Dyhrfjeld-Johnsen, 2016). Daily intraperitoneal treatment with azasetron for 14 days, but not with other setrons, after 2 hours of exposure to intense 120-dB octave noise significantly reduced hearing loss and increased survival of sensory hair cells. Azasetron is a chiral molecule with two enantiomers, R and S, and additional experimentation demonstrated that the R-enantiomer was significantly more effective in treating acoustic trauma–induced sudden sensorineural hearing loss, due to significantly higher levels of drug exposure of R-azasetron in the inner ear after oral administration than for the racemic mixture or the isolated S-enantiomer (Dyhrfjeld-Johnsen, 2017). Further animal studies have shown that R-azasetron is equally effective in protecting from hearing loss and sensory cell death induced by administration of the chemotherapeutic drug cisplatin, another well known etiology of sensorineural hearing loss and debilitating treatment-related side effects for patients with cancer (Petremann et al., 2017).

The findings summarized here clearly underline the potential use of specific 5-HT3 antagonists in the treatment of inner ear diseases. However, the experimental results discussed also highlight the complexity of setron family pharmacology and pharmacokinetics, emphasizing the need to take into account specific characteristics of these compounds as well the translational relevance of animal models.

Multiple studies have highlighted the potential neuroprotective properties of ondansetron and tropisetron (Rahimian et al., 2011a, 2013b; Venail et al., 2012; Aminian et al., 2013; Dyhrfjeld-Johnsen et al., 2013; Swartz et al., 2013), consistent with their capacity for inhibiting the protein phosphatase calcineurin-involved neurodegenerative cascades (de la Vega et al., 2005; Rahimian et al., 2011b). These results with R-azasetron are consistent with a neuroprotective effect through calcineurin inhibition (Dyhrfjeld-Johnsen, 2016, 2017; Petremann et al., 2017), as is the lack of a protective effect for granisetron since this setron does not inhibit calcineurin (de la Vega et al., 2005; Rahimian et al., 2011b). The contradictory lack of the protective effect of calcineurin-inhibiting setrons ondansetron and tropisetron against acoustic trauma could be explained through another aspect of their complex pharmacology, namely the reduction of ACh-mediated inhibition of inner ear sensory hair cells through antagonism of α9α10 nAChR channels (Rothlin et al., 2003). Although calcineurine inhibition by ondansetron and tropisetron could in principle be neuroprotective, their disinhibition of already stressed inner ear sensory cells through significant α9α10 nAChR antagonism would contribute to further depolarization, excitotoxicity, and calcium influx, canceling out neuroprotective properties and potentially even driving the balance toward neurodegeneration and cell death. In regard to drug-induced toxicity by chemotherapy agents such as cisplatin, ondansetron has been shown to increase nephrotoxicity in animal models through inhibition of the multidrug and toxin extrusion transporter family (Li et al., 2013). Because multidrug and toxin extrusion transporters are also expressed in the inner ear (Gaboyard-Niay, 2013), inhibition of toxin extrusion transporters could equally contribute to enhanced ototoxicity resulting in worsening of hearing and balance.

In conclusion, the neuroprotective potential of 5-HT3 antagonists is highly interesting for inner ear pathologies; however, the complex pharmacology and pharmacokinetic properties of the setron family compounds must be taken into account in a tissue- and disease-specific manner, with respect to the potential selection of candidates for drug development. R-Azasetron has successfully completed the clinical phase I stage and is currently in development for use in protection against sudden sensorineural hearing loss and prevention of platinum-induced ototoxicity, based on its unique drug candidate profile combining neuroprotective calcineurin inhibition and high local target exposure in the apparent absence of deleterious disinhibition of sensory hair cells or modulation of transporters augmenting ototoxicity. This makes R-azasetron ideally suited for treating lesions of the inner ear, where exact etiology and involvement of cochlear and vestibular substructures cannot be clearly distinguished based on current diagnostic testing of functional deficits.

F. Stroke

Stroke is a leading cause of death and long-term disability worldwide. Development of an effective therapeutic strategy for stroke has been a priority of neuroscience research for decades. To date, the results of several clinical trials for pharmacotherapy of stroke have been frustrating, with recombinant tissue plasminogen activators as the only agents approved by the U.S. Food and Drug Administration. Elucidation of novel cellular
and molecular pathways that influence the pathogenesis of stroke could lead to the development of new therapeutic approaches (Kriz and Lalancette-Hébert, 2009; Lee et al., 2014). The first set of studies with 5-HT₃R antagonists indicated that these agents lack any beneficial effect in the transient middle cerebral artery occlusion model of stroke (Candelario-Jalil et al., 2008). On the other hand, 5-HT₃R antagonists display neuroprotective properties in vitro and in vivo. In fact, oxidative stress–induced injury in rat cortical neurons was counteracted through curtailing caspase-3 activation, calcium influx, reactive oxygen species generation, and excitotoxicity. The observed protection was shown to be mediated through blockade of 5-HT₃Rs by means of employing selective 5-HT₃Ra antagonists (Lee et al., 2005b). In rat hippocampal slices, stimulation of 5-HT₃R exacerbated the ischemia-induced decrease in CA1 field potential, whereas antagonism of 5-HT₃R produced dose-dependent neuroprotection against the ischemia-induced neuronal injury (Kagami et al., 1992).

In vivo, tropisetron was also found to be beneficial in an embolic model of stroke (Rahimian et al., 2011a).

1. Modulation of Molecular Pathways. Different signaling pathways might explain the neuroprotective aspects of 5-HT₃R antagonists after ischemic insults. The first, as discussed earlier, is the calcineurin pathway. Briefly, 5-HT₃R antagonists inhibit aberrant calcineurin phosphatase activity via receptor-dependent and independent mechanisms, culminating in poststroke neuroprotection (Rahimian et al., 2011a,b). The second is activation of α7 nAChR, an essential mediator of the cholinergic anti-inflammatory pathway (Kohnomi et al., 2010; Stegemann et al., 2013). In addition to neurons, α7 nAChR is expressed on a wide spectrum of immune cells, and its activation is shown to inhibit proinflammatory cytokine production from macrophages and microglia, adhesion molecule expression, and T-cell proliferation. In vivo, α7 nAChR stimulation effectively attenuates immune responses and ameliorates disease severity in various experimental settings. Activation of phosphoinositide 3-kinase/Akt (Rehani et al., 2008) and Janus kinase/signal transducer and activator of transcription 3 (Yu et al., 2009) cascades is implicated in the anti-inflammatory actions of α7 nAChR (Fig. 1). Activation of this pathway, however, can only explain the neuroprotective properties of tropisetron, as other congeners do not affect α7 nAChR. The third plausible mechanism is potentiation of endocannabinoid-mediated anti-inflammatory signaling in the CNS, which is also confined to tropisetron. Indeed, tropisetron upregulates cannabinoid type 1 receptor (CB₁R) expression at both transcriptional and translational levels in cultured cerebellar granule neurons. This effect is accompanied by a decrease in the CB₂R secondary messenger, cAMP. Intriguingly, treatment of cerebellar granule neurons with granisetron did not affect the expression of CB₁R or its function (Rahimian et al., 2011b). Finally, the last possible mechanism, which corroborates the neuroprotective profile of setrons, is PPARγ activation. Tropisetron attenuates gut inflammation through PPARγ induction after resect acetic acid instillation. The protective effect is diminished in the presence of PPARγ receptor antagonist GW9662 (Rahimian et al., 2016). The same mechanism could underpin the action of 5-HT₃R antagonists in cerebral ischemia models, since the PPARγ agonist pioglitazone leads to a prominent improvement in transient middle cerebral artery occlusion in rats (Deplanque et al., 2003; Shimazu et al., 2005; Sundararajan et al., 2005; Bordet et al., 2006a). However, it is currently unknown whether the induction of PPARγ transcriptional activity is receptor mediated or through direct interaction with PPARγ.

2. Possible Effects on Microglia. Microglia respond dynamically to ischemic injury, experiencing both pro- and anti-inflammatory phenotypes. These dual and opposing roles of microglia suggest that stroke therapies should be shifted from simply suppressing microglia toward adjusting the balance between beneficial and detrimental microglia/macrophage responses (Rahimian et al., 2018, 2019). Some studies indicate that increased transcriptional activity of PPARγ can promote alternative microglia activation (Bordet et al., 2006b; Patel et al., 2013). Changing the microglia polarization could be an important mechanism by which 5-HT₃R antagonists elicit protective effects after brain ischemia. Tropisetron-induced microglia polarization could have notable clinical significance. Microglia constitutes self-renewing and long-lived resident macrophage-like cells of the brain. Although the precise roles of microglia in neuroinflammation have not been yet fully deciphered, recent studies strongly suggest their various essential functions in neurodegenerative contexts where they can act as a double-edged sword. Microglia phagocytose tissue debris and secrete proinflammatory cytokines, ensuing further damage (Patel et al., 2013). In contrast, they can also secrete anti-inflammatory mediators to alleviate inflammation.

Stroke has a complex pathology and many different cells, including neurons, microglia, and astrocytes, are involved in the pathogenesis of stroke. Some studies have reported neuroprotective effects for 5-HT₃R antagonists both in vitro and in vivo, and various 5-HT₃R–dependent and 5-HT₃R–independent mechanisms have been proposed. 5-HT₃R antagonists might affect the phenotype and polarization of nonneuronal populations such as microglia after stroke. Given that these cells do not express functional 5-HT₃Rs (Krabbe et al., 2012), other serotonin-independent mechanisms such as regulation of intracellular pathways through modulation of other cell surface receptors or directly engagement with intracellular targets might be involved in the effects of setrons on glia. Yu et al. (2018) showed that tropisetron curtails microglial activation and therefore attenuated lipopolysaccharide (LPS)–induced neuroinflammation.
in the cerebral cortex by targeting the neuronal population, a mechanism previously reported for other setrons in colonic inflammation (Utsumi et al., 2016). Tropisetron, by antagonizing 5-HT₃R on neurons, diminishes substance P release from nerve endings onto the neurokinin 1 receptor on microglia. The resultant decrease in nuclear factor-κB (NF-κB) activity downstream of neurokinin 1 receptor stimulation leads to less production of proinflammatory cytokines in the cortex and a milder neuroinflammatory phenotype (Yu et al., 2018).

Although the 5-HT₃R subtype is not expressed by microglia (Krabbe et al., 2012), many of the findings in vivo with the setron family (mostly tropisetron) imply a microglial component in their effects. This might stem from a crosstalk between 5-HT₃R-expressing cell populations and microglia and/or from engagement of other targets of tropisetron expressed by microglia. Other possible mechanisms underlying setron-induced microglial alternative activation could rely on other types of membrane receptors such as nicotinic receptors or intracellular targets such as calcineurin, MAPK, and PPARγ.

3. Effect on Diabetes and Glucose Intolerance as Risk Factors for Stroke. The role of 5-HT₃R has been investigated in glucose metabolism and pathogenesis of diabetes in vivo and in vitro. Central 5-HT₃R stimulation by m-CPBG has been shown to increase blood glucose in stressed rats and this effect is surmountable by administration of the 5-HT₃R antagonist ondansetron (Carvalho et al., 2002). Another report indicates that functional integrity of the brain corticotropin-releasing hormone (CRH) system and 5-HT₃Rs is needed for serotonergic agonist-induced hyperglycaemia (Carvalho et al., 2002, 2005; Fakhfouri et al., 2012). In vitro, 5-HT₃R antagonists were found to enhance insulin release by INS-1 cells. The effect was interestingly more pronounced in the presence of serotonin. Serotonin reduced the glucose-stimulated release of insulin in a concentration-dependent manner, whereas tropisetron abolished this inhibition (Heimes et al., 2009). Such
observation points out the involvement of 5-HT₃Rs in tropisetron-induced insulin secretion. In vivo, tropisetron has been shown to induce PPARγ transcriptional activity and to be beneficial in cerulein-induced acute pancreatitis in mice (Rahimian et al., 2016, 2017). These effects highlight the ability of 5-HT₃R antagonists in regulating blood glucose levels. Since glucose intolerance and diabetes constitute one of the most important risk factors for ischemic stroke (Olsson et al., 1990), 5-HT₃R antagonists have the potential to be investigated in this subset of patients. Their anti-inflammatory and memory-enhancing effects, alongside their positive effects in balancing blood glucose levels, make them a potential candidate to rescue brain damage after stroke (Rahimian et al., 2013a).

V. 5-HT₃ Receptor Antagonists in Psychiatric Disorders

5-HT₃Rs are implicated in emotion- and cognition-governing neural processes and antagonists of these receptors are shown to be beneficial in the treatment of various psychiatric disorders (Hammer et al., 2012).

A. Depression

Major depressive disorder is a common psychiatric disorder typified by persistent low mood, cognitive impairment, volitional decline, and somatic symptoms (Cai et al., 2015). Despite the availability of various classes of antidepressants, treatment of depression is hampered by insufficient and nonuniversal efficacy as well as untreated or residual cognitive impairment, warranting newer alternatives. 5-HT₃R antagonists stand out as a good candidate.

Various ligands with antagonistic activity at 5-HT₃R acutely reduce immobility time in the forced swim test (FST) (Mastorakos et al., 1993) and tail suspension test (Gupta et al., 2014b). In addition, tropisetron, zacopride, and ondansetron abolish learned helplessness in rats when administered on a chronic schedule, suggesting a class effect (Martin et al., 1992). In chronic depression models rendered either by exposure to chronic unpredictable stress or repeated corticosterone administration, 5-HT₃R antagonists reverse depressive behavior in mice (Gupta et al., 2014a,b, 2015).

1. Modulation of Putative Neuropathology. Many of the neuropathologic mechanisms associated with major depressive disorder appear to be modulated by 5-HT₃Rs and their antagonists. This might distinctly underpin the acute and chronic antidepressant-like actions of 5-HT₃ antagonists repeatedly reported in diverse animal models. The LC, the main nucleus for norepinephrine (NE) synthesis, receives a dense innervation from the 5-HT–producing dorsal raphe nucleus (DRN) (Levitt and Moore, 1978). Stimulation of this serotonergic projection curtails activity of noradrenergic neurons in the LC (Segal, 1979). Using dual-probe microdialysis in awake rats and electrophysiological techniques on brainstem sections, Ortega et al. (2012) demonstrated that activation of 5-HT₃R stimulates NE release in the LC, which induces sequentially a decrease in the firing rate of LC neurons through α2 adrenergic autoreceptors and a decrease of NE release in terminal areas such as the PFC. Therefore, the NE-depleted PFC of patients with depression could be hypothetically replenished by prescription of 5HT₃R antagonists.

5-HT₃Rs expressed on a subset of GABAergic interneurons in the hippocampus and PFC serve as regulators of GABA release and therefore glutamatergic transmission by 5-HT (Puig et al., 2004). Electrophysiological studies demonstrate that stimulation of 5-HT₃R inhibits both the spontaneous and N-methyl-D-aspartate–induced firing of pyramidal neurons in the rat medial PFC (Ashby et al., 1991; Liang et al., 1998). In line with this, pharmacological blockade of 5-HT₃R increases the firing activity of glutamatergic pyramidal cells via disinhibition (Reznic and Staubli, 1997) (Fig. 2).

Vortioxetine provides further evidence for the engagement of 5-HT₃R ligands in the modulation of neurotransmitter release and antidepressant activity. This multimodal agent combines the SSRI mode of action (i.e., inhibition of the serotonin transporter) with 5-HT₃ antagonism to augment 5-HT availability in synapses (Stahl, 2015). The latter most likely contributes to vortioxetine’s clinical antidepressant effects (Pehrson and Sanchez, 2014; Sanchez et al., 2015). The blockade of 5-HT₃R by vortioxetine disinhibits pyramidal neurons through elimination of GABAergic inhibition. The resultant increase in glutamatergic transmission stimulates serotonergic neurons in the raphe nucleus to release 5-HT (Stahl, 2015). Similarly, ondansetron demonstrates synergistic antidepressant-like effects in the FST when used as an adjunct to SSRIs (Redrobe and Bourin, 1997; Bétrly et al., 2015). The effect is most likely due to the enhancement of SSRI action on extracellular 5-HT through 5-HT₃R blockade.

Anhedonia has been linked with disruptions in the mesolimbic DA circuit (Nestler and Carlezon, 2006). Although neurochemical studies generally fail to support a role for 5-HT₃R in mesolimbic DA release under basal conditions (Koulu et al., 1989; Invernizzi et al., 1995), phasic DA cell firing and transmission consistently show positive modulation by 5-HT₃R in both the NAc and VTA (Campbell et al., 1996; De Deurwaerdere et al., 1998). Thus, 5-HT₃R antagonists inhibit drug-evoked/ altered DA release in the mesolimbic pathway presumably via a presynaptic mechanism (Chen et al., 1991). The translatability of the electrophysiological and biochemical observations in anhedonia was assessed by a study using the chronic unpredictable stress–evoked depression model. In this setting, prolonged administration of ondansetron at doses as low as 0.05 mg/kg to mice with an established depressive
phenotype was sufficient to reduce floating time in the FST and increased consumption of sucrose in the sucrose preference test. The effect mirrored that of antidepressant fluoxetine and was accompanied by correction of the hyperactive hypothalamic-pituitary-adrenal (HPA) axis, as revealed by normalization of elevated plasma corticosterone levels (Gupta et al., 2014a). Corroborating to the observed effect of 5-HT$_3$R antagonism on the HPA axis, mice lacking 5HT$_3$A exhibited dampened adrenocorticotropic hormone responses to acute stressors, including LPS and restraint, with no change in pituitary sensitivity to CRH (Bhatnagar et al., 2004). The effects of 5-HT$_3$R antagonists on neuronal networks are summarized in Fig. 2.

Regarding the presence of an inflammatory milieu in depression (Cai et al., 2015), setrons can foster benefit owing to their anti-inflammatory properties as substantiated in peripheral inflammatory conditions (Stratz et al., 2002; Tolk et al., 2004; Müller et al., 2006). In vitro, tropisetron and ondansetron exhibit anti-inflammatory effects on LPS-challenged human monocytes by specifically inhibiting tumor necrosis factor-α and IL-1β secretion while minimally affecting other cytokines or chemokines (Fiebich et al., 2004a). The effect is exerted at the posttranscriptional level and presumably mediated by inhibiting the activating phosphorylation of p38 MAPK (Stratz et al., 2012).

As stated in section IV.F, 5-HT$_3$R antagonism can induce PPARγ transcriptional activity (Rahimian et al., 2016). This effect has an established antidepressive outcome in both animal and human studies (Eissa Ahmed et al., 2009; Sepanjnia et al., 2012).

2. Pharmacological Action of Antidepressants on 5-HT$_3$ Receptors. 5-HT$_3$Rs might constitute a site of action for prescribed antidepressants. In 1994, for the first time, the prototypes of three different classes of these agents were shown to block inward currents mediated by endogenous 5-HT$_3$Rs on primary rat nodose ganglion neurons (Fan, 1994). In patch-clamp recordings, the tricyclic antidepressant (TCA) imipramine (which inhibits reuptake of both NE and 5-HT), the SSRI fluoxetine, and monoamine oxidase inhibitors phenelzine and iproniazid markedly inhibited cation peak current and accelerated desensitization of 5-HT$_3$ channels. The functional antagonism appears to result from a direct action on 5-HT$_3$Rs rather than engaging secondary messengers, since intercellular application of either general protein kinase inhibitors or a calcium chelator failed to alter the effects of any antidepressant on 5-HT$_3$ current kinetics (Fan, 1994).

A decade later, this list was complemented with antidepressants from newer categories. In fact, reboxetine, an NE reuptake inhibitor, and mirtazapine, an atypical antidepressant with noradrenergic and specific serotonergic activity, as well as first- and second-generation TCAs proved potent inhibitors of 5-HT-evoked calcium and sodium currents at therapeutically relevant concentrations. The currents were measured at recombinant 5-HT$_3$A receptors on human embryonic kidney 293 cells and endogenous 5-HT$_3$Rs on murine primary and immortal neurons (Eisensamer et al., 2003). The non-competitive nature of blockade exhibited by all antidepressants but mirtazapine suggests the involvement of an interaction site distinct from the agonist binding site, leading to an allosteric modulation of this ligand-gated ion channel by antidepressants (see the section II.C).

In summary, antidepressants possess a similar profile on 5-HT$_3$R current kinetics despite disparate molecular structures and distinct putative mechanisms of action. In addition, 5-HT$_3$R antagonists

![Fig. 2. Effects of 5HT$_3$R antagonists on neurotransmitter systems and the HPA axis.](image-url)
display antidepressant activity in various preclinical settings. Therefore, it is plausible that 5-HT₃Rs serve as a yet unappreciated target of antidepressant action and antagonism of this ion channel receptor can emerge as a novel strategy toward an effective and more selective pharmacotherapy. In conformity with this notion, the TCA-induced decreased duration of immobility of mice in the FST is also reversed by m-CPBG, a 5-HT₃R agonist (Nakagawa et al., 1998).

3. Human Genetic Findings. In genetic studies, the high-frequency polymorphism encoding the Y129S variant in the 5-HT₃B subunit was shown to be inversely correlated with the incidence of major depression in women (Yamada et al., 2006). Importantly, human heteromeric 5-HT₃AB receptors containing the Y129S variant display unaltered surface expression levels but altered functional properties (Walstab et al., 2008), including a dramatically augmented maximal response to serotonin and slower desensitization and deactivation kinetics (Krzywkowski et al., 2008). This profile suggests that increased 5-HT₃AB receptor-mediated neurotransmission of serotonin may controversially confer protection against the development of major depression in females.

For dedicated reviews on the role of 5-HT₃R in depression, see Rajkumar and Mahesh (2010), Bétrly et al. (2011), and Gupta et al. (2016).

B. Anxiety

Anxiety disorders were classified according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders as panic disorder, generalized anxiety disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), specific phobia, and obsessive-compulsive disorder (OCD) (Ravindran and Stein, 2010). In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, OCD has been placed in a new category, obsessive-compulsive and related disorders (Van Ameringen et al., 2014). Antidepressant drugs are prescribed for both depression and anxiety disorders, suggesting some overlap between the underpinning neuropathologies.

The animal tasks commonly used to test the anxiolytic properties of compounds comprise rodent conflict models of anxiety such as the dark-light emergence test, exploration tests including the elevated plus maze and open field tests, and social tasks such as social competition and social interaction tests (Rodgers, 1997).

A role for 5-HT₃R in anxiety-related behaviors has been the subject of several studies, and antagonists, including tropisetron, granisetron, ondansetron, and zacopride, have repeatedly demonstrated an array of antianxiety effects in various experimental models of anxiety. Nevertheless, they display differential efficacy across and within experiments and there are reports indicating that they have no effect (Jones et al., 1988; Costall and Naylor, 1992; Filip et al., 1992).

In an attempt to identify the neuropathological sites of anxiolytic-like action of 5-HT₃R antagonists, Costall et al. (1989) injected male mice with tropisetron and ondansetron in various brain regions. Although microinjection in the medial raphe nucleus, striatum, and NAc was without effect, 5-HT₃R blockade in the amygdala and DRN gave rise to a behavioral profile in the dark/light box test that was very similar to that caused by diazepam (Costall et al., 1989), thus uncovering the cerebral topography for the antianxiety effects of this class.

Further evidence for the involvement of 5-HT₃R in anxiety-related behaviors lies in the findings of a study on anabolic androgenic steroid (AAS)–treated hamsters. Concomitant provocation of aggression and reduction of anxious behaviors during exposure to AAS in adolescence was accompanied by a downregulation of 5-HT₃R across the regions associated with both aggression and anxiety, including the anterior hypothalamus, medial amygdala, central amygdaloid nucleus, and bed nucleus of the stria terminalis (Morrison et al., 2015). The relevance of such molecular alteration to the anxiolytic outcome of AAS treatment, as assessed in the elevated plus maze test, was proven by the loss of the effect upon 5-HT₃R agonist treatment.

In emotional processing tasks with demonstrated sensitivity to SSRI administration, antagonism at 5-HT₃ was shown to abolish the emotion-potentiated startle effect in healthy subjects. This observation corroborates the anxiolytic actions of 5-HT₃R antagonism in animal models and suggests the engagement of 5-HT₃R in certain physiologic aspects of fear fear in and in the effects of serotonergic manipulations on anxiety in humans (Harmer et al., 2006).

Accordingly, in genetic studies, targeted gene deletion of the 5-HT₃A receptor in mice led to decreased indices of anxiety in the elevated plus maze, novel object interaction, and dark-light emergence tests (Kelley et al., 2003a), whereas in another study the same genotype was associated with the anxiolytic-like phenotype in the elevated plus maze test but not the dark-light box test (Bhatnagar et al., 2004). 5-HT₃A null mice also exhibited dampened adrenocorticotropic hormone responses to distinct acute stressors, including LPS and restraint, indicating that 5-HT₃A deletion affects stress-induced but not basal HPA activity. However, CRH levels were unaltered after the same acute challenges and pituitary corticotroph sensitivity to the stimulatory effects of exogenous CRH remained similar in wild-type and knockout mice (Bhatnagar et al., 2004). Intracerebroventricular administration of bemesetron, a 5-HT₃A receptor antagonist (Table 1), also blunted the corticosterone response to acoustic stress (Saphier et al., 1995), suggesting that the 5-HT₃A receptor normally has a general stimulatory effect on acute stress-induced HPA activity.

1. Human Genetic Findings. Functional magnetic resonance imaging studies demonstrate that a single
nucleotide polymorphism (SNP) identified in the regulatory region of HTR3A is correlated with higher activity in the amygdala and PFC as well as greater anxiety symptoms during emotional and nonemotional tasks in humans (Iidaka et al., 2005; Kilpatrick et al., 2011). The same polymorphism was found to modulate receptor expression through altering its translation rate in vitro (Niesler et al., 2001), lending more support to a link between 5-HT3R and anxiety.

2. Obsessive-Compulsive Disorder. OCD, as its name suggests, is characterized by recurrent, intrusive, and distressing thoughts, images, or impulses (obsessions) and repetitive, seemingly purposeful behaviors that a person feels compelled to perform (compulsions) (Soltani et al., 2010).

The most studied animal behavioral batteries of OCD comprise 8-hydroxy-2-(di-n-propylamino)-tetralin hydrobromide–induced decreased alternation, quinpirole-induced compulsive checking, marble burying, signal attenuation, and spontaneous stereotypy in deer mice (Albelda and Joel, 2012). It should be kept in mind, however, that animal models reflect only a fraction of human behavior due to the complexity of OCD symptoms.

Based on neuroimaging studies in human subjects with OCD, the regions most consistently associated with pathophysiology of symptoms are the cingulate cortex, orbitofrontal cortex, basal ganglia, and parietal lobe. Dysfunction of multiple neurotransmission circuits has been implicated in the pathophysiology of the disorder, including serotonergic, dopaminergic, and glutamatergic systems. Dysregulation of the serotonergic system has been primarily suggested due to the effectiveness of SSRIs in alleviating obsessions and compulsions in patients (Zohar and Insel, 1987; Zohar et al., 1992) and has received further support from neurobiological, pharmacological, and more recently genetic data (Albelda and Joel, 2012).

a. Clinical Findings. In double-blind placebo-control pilot clinical trials, ondansetron treatment as an adjunct to fluoxetine as well as a low-dose granisetron add-on to fluvoxamine, both prescribed for 8 weeks to nonmedicated subjects with OCD, improved obsessive and compulsive symptoms (Soltani et al., 2010; Askari et al., 2012). The ondansetron add-on, given at low doses for 12 weeks, was also effective in reducing Yale-Brown Obsessive-Compulsive Scale scores in patients who were unresponsive to conventional OCD medications (Pallanti et al., 2009).

In light of these findings, the new generation of multimodal agents such as vortioxetine, which also antagonizes 5-HT3R, might prove more efficacious in controlling OCD symptoms than their predecessors.

b. Human Genetic Findings. Genetic findings in patients with OCD substantiate the clinical benefit of setrons in this disorder. HTR3D variant rs1000592 demonstrated a significant association with OCD, whereas HTR3C variant rs6766410 was linked with OCD only in male individuals. Among patients with OCD, HTR3E variant rs7627615 coded for higher scores in the washing subtype and worse visual organization (Lennertz et al., 2014).

3. Post-Traumatic Stress Disorder, a Different Case. An accepted animal model for PTSD is Pavlovian fear conditioning, which sufficiently mimics the traumatic events that induce symptoms of an intense and recurrent fear characteristic of patients with PTSD (Zovkic and Sweatt, 2013). Setrons have not yet been tested in PTSD models. However, a key study showed that 5-HT3A knockout mice exhibited a significant enhancement of conditional freezing and a blunted fear response extinction in the fear conditioning task in contrast to their anxiolytic behavior in the elevated plus maze test (Bhatnagar et al., 2004). Using a different fear conditioning protocol, another group reported no change in acquisition of fear memory but a significantly impaired extinction of learned fear in 5-HT3A knockout mice (Kondo et al., 2013).

The aggravated fearful behavior of knockouts in classic conditioning could emanate from 5-HT3A deficit-provoked perturbations in neural circuits of brain structures engaged in fear conditioning. These major players are the amygdala, which governs acquisition and extinction of fear memory; the PFC, which regulates the amygdala; and the hippocampus, which encodes the context in which the CS-US association is learned, expressed, and extinguished (LeDoux, 2015). As mentioned earlier, 5-HT3Rs are abundantly found on GABAergic interneurons in all of these regions. One possibility is that 5-HT3A receptor ablation reinforces fear memory by influencing the formation of CS-US association in the amygdala, which receives major serotonergic inputs from the DRN (Ma et al., 1991). In mechanically dissociated BLA neurons with intact presynaptic nerve terminals, stimulation of presynaptic 5-HT3R facilitates GABA release from interneurons, whereas this effect is blocked by 5-HT3R antagonism (Koyama et al., 1999). Therefore, it is plausible that disruption of serotonergic-mediated GABAergic release leads to disinhibition of glutamatergic principal neurons of BLA, which in turn, project to and excite central amygdala to drive a heightened fear response.

The enhancement of fear conditioning in the absence of functional 5-HT3A receptors suggests that despite their documented anxiolytic properties, 5-HT3R antagonists might precipitate symptoms in patients with PTSD.

4. Advantageous Adverse Effect Profile of 5-HT3 Receptor Antagonists. 5-HT3R antagonists are advantageous over anxiolytic benzodiazepines routinely used in anxiety disorders, in that they do not possess sedative/hypnotic properties and are not associated with dependence or withdrawal issues after discontinuation of long-term use (Faerber et al., 2007) (Fig. 3). A lack of sedative...
and motor-incapacitating effects has also been observed in animal models (Costall and Naylor, 1992) although anxiolytic behavioral profile of 5-HT3R antagonists replicates that of benzodiazepines. This is of particular clinical significance and emerges from the fact that, in stark contrast to classic anxiolytics, 5-HT3R antagonists are devoid of either direct agonistic action on GABA receptors or a potentiating effect on GABAergic neurotransmission (Carboni et al., 1989b). In fact, as mentioned earlier, antagonism of 5-HT3R appears to curtail the synaptic release of GABA (Turner et al., 2004) (Fig. 2).

C. Schizophrenia

Schizophrenia has been primarily associated with DA dysfunction, and treatments have been developed that target the DA pathway in the CNS (Grace, 2016; Yang and Tsai, 2017). However, existing medications control the positive symptoms in only half of patients, while leaving negative symptoms and cognitive impairment mostly untreated (Stepnicki et al., 2018). There remains an enormous need for a better appreciation of schizophrenia pathophysiology and development of novel treatment approaches. Emerging evidence from genome-wide association studies goes beyond the DA type 2 receptor (as the target of antipsychotics) and extends the schizophrenia association to proteins in glutamatergic neurotransmission and synaptic plasticity (Ripke et al., 2014).

Efficacy of 5-HT3R antagonists has been tested in experimental settings. Similar to typical (haloperidol) and atypical (sertrindole) antipsychotics (Valenti et al., 2011), chronic administration of granisetron and its analog BRL 46470A reduces the number of spontaneously active DA neurons in the VTA. The effect appears to follow a multiphasic dose-response pattern and, unlike antipsychotics, is not mediated by depolarization block (Ashby et al., 1994).

Abnormality in auditory-evoked P50 potential is regarded as a neurophysiological endophenotype (Hazlett et al., 2015) of schizophrenia and may constitute a sensitive biomarker for patient response to medication. In DBA/2 mice, a single dose of tropisetron attenuated the spontaneously developed deficit in the hippocampus P20–N40, a rodent analog of P50 sensory gating. The effect was offset upon coadministration of an α7 nAChR antagonist (Hashimoto et al., 2005) and was recapitulated by using a pure agonist at this receptor subtype (Simosky et al., 2001), raising the possibility that tropisetron agonistic activity on α7 nAChR is the underpinning mechanism. However, the same α7 nAChR-dependent effects were observed with ondansetron, a sotrin with no affinity for α7 nAChR (Wildeboer et al., 2009). Similar to the animal findings, ondansetron attenuated P50 sensory gating in medicated patients (Adler et al., 2005). Inhibition of 5-HT3R releases ACh, the endogenous ligand for nAChRs. Indirect stimulation of nAChRs by ondansetron therefore can improve auditory gating parameters in DBA/2 mice.

Cognitive deficits are an integral part of schizophrenia-related symptoms, which manifest as disruption of

![Fig. 3. Advantageous therapeutic profile of 5HT3R antagonists over conventional medications prescribed for psychiatric disorders.](image-url)
memory (working, visual, and verbal), executive functioning, sustained attention, and processing speed. These manifestations often precede other symptoms and respond inadequately to antipsychotic therapy (Harvey et al., 2004). Ondansetron reverses amphetamine-derived impaired latent inhibition when given at a low dose to rats and improves learning and memory (Akhondzadeh et al., 2009).

1. Pharmacological Action of Antipsychotics on 5-HT₃ Receptors. Similar to the effects of antidepressants, unrelated classes of antipsychotics, including phenothiazines, thioxanthenes, and butyrophenones, colocalize with 5-HT₃Rs in plasma membrane raft-like domains (Eisensamer et al., 2005) and demonstrate a potent antagonism against 5-HT-evoked sodium and calcium currents (Hermann et al., 1996; Rammes et al., 2004), suggesting a role for 5-HT₃Rs in their antischizophrenic efficacy. This observation was made with both the endogenous murine neuronal 5-HT₃R and the recombinant human 5-HT₃₅A receptor stably expressed in human embryonic kidney 293 cells, with different profiles on peak and plateau (Rammes et al., 2004). With the exception of clozapine, which is a known competitive antagonist at the 5-HT₃₅A receptor (Watling et al., 1990; Wang et al., 1994), all antipsychotics tested displayed an insurmountable antagonistic action, as evidenced by their inability to displace a selective competitive 5-HT₃R radioligand from the membrane fractions and supported by electrophysiological data. The effect was voltage independent and more pronounced after preincubation with any given antipsychotic, suggesting that the antagonism is not exerted through an open-state blockade (Rammes et al., 2004).

Because of the structural similarity that exists between 5-HT₃R and α7 nAChR, one might think of ligands with therapeutically relevant affinities for both receptors. Indeed, tropisetron constitutes one such compound, acting as a partial agonist on the nicotinic receptor subtype. This dual action can be of particular benefit in the case of schizophrenia; α7 nAChR has been linked to the sensory gating deficits frequently reported in schizophrenia (Adler et al., 1998).

2. Antipsychotic-Induced Parkinsonism. A multitude of experimental studies have demonstrated the ameliorating effect of 5-HT₃R antagonists on antipsychotic-induced extrapyramidal symptoms (Silva et al., 1995; Zhang et al., 2006; Akhondzadeh et al., 2009; Ohno et al., 2011; Tatara et al., 2012). The underpinning mechanisms remain elusive but advances have been made over the last decade. Both systemic injection and local administration of ondansetron into the striatum inhibit bradykinesia induction (Ohno et al., 2011, 2015), implying that postsynaptic 5-HT₃Rs are somehow implicated in the induction or facilitation of antipsychotic-evoked extrapyramidal symptoms. As 5-HT₃R agonists stimulate glutamate release in different brain areas (Ashworth-Preece et al., 1995; Funahashi et al., 2004; Jeggo et al., 2005), it is plausible that 5-HT₃R antagonists exert their beneficial effect by limiting glutamate release in the striatum (Ohno et al., 2015).

Finally, 5-HT₃R antagonist adjunct therapy may be of additional benefit to antipsychotic-associated tardive dyskinesia, an irreversible motor side effect of long-term antipsychotic treatment. Both tropisetron and ondansetron dose-dependently reverse haloperidol-induced vacuous chewing movements, a rodent analog of tardive dyskinesia; therefore, a 5-HT₃R antagonist class effect is conceivable (Naidu and Kulkarni, 2001).

3. Clinical Findings. 5-HT₃R antagonists as an add-on therapy have shown promising effects against the most intractable symptoms of schizophrenia, namely negative and cognitive symptoms. In treatment-resistant patients with chronic schizophrenia, the addition of ondansetron for 12 weeks significantly improved negative symptoms, general psychopathology, and cognition and significantly lowered the incidence and severity of haloperidol-induced parkinsonism and akathisia (Silva et al., 1995; Zhang et al., 2006; Akhondzadeh et al., 2009; Ohno et al., 2011; Tatara et al., 2012). Ondansetron was associated with attenuation of negative symptoms as well as visual memory correlates, including visual reproduction, visual paired associate learning, and figural memory, when administered as an adjunct to risperidone-medicated patients (Akhondzadeh et al., 2009). Similarly, in a double-blind, placebo-controlled 8-week trial, the addition of tropisetron to risperidone improved the primary negative symptoms of patients with chronic stable schizophrenia with no additional adverse effects (Noroozian et al., 2013). Add-on therapy with tropisetron as short as 10 days could also improve cognitive impairments in patients stabilized on risperidone (Zhang et al., 2012).

In addition to schizophrenia symptoms, this class of drugs also shows promise for the alleviation of nonmotor symptoms for patients with PD, including medication-induced psychosis and behavioral side effects (Zoldan et al., 1996; Ohno et al., 2015). Indeed, in an open-label study conducted over 4–8 weeks, daily doses of ondansetron given to patients with l-dopa–associated psychosis of 6- to 60-month duration ameliorated paranoid delusions, visual hallucinations, confusion, and related global functional impairment. Interestingly, this add-on therapy was well tolerated and did not affect the efficacy of l-dopa in controlling the main symptoms of PD (Zoldan et al., 1995).

4. Human Genetic Findings. Genetic studies implicate the 5-HT₃E subunit in cognition-related endophenotypes in schizophrenia. Sustained attention was evaluated using the continuous performance test in healthy controls as well as in patients who were stable while taking medication. Of six common functional and coding variants of the subunit genes, 5-HT₃ variant rs7627615 was associated with better attentional capacities in individuals from both cohorts.
(Lennertz et al., 2010). In pharmacogenetic studies, the same HT3RE SNP codes for a faster response to antipsychotic treatment. Patients harboring this variant displayed a quicker improvement in negative symptoms when treated with risperidone or haloperidol (Schuhmacher et al., 2009). In a case-control study conducted in a South Indian population, a significant association was observed for HT3RA functional variant rs1062613 (Jajodia et al., 2015).

5. Advantageous Adverse Effect Profile. In terms of adverse effects, 5-HT3R antagonists are advantageous over both antipsychotic classes. Unlike the first generation antipsychotic classes, the lack of interaction with DA D2R, setrons do not promote and, as stated above, may even act to counteract tardive dyskinesia (Naidu and Kulkarni, 2001). Moreover, unlike atypical antipsychotics that cause insulin intolerance and obesity (MacKenzie et al., 2018), setrons lack metabolic effects and rather exert a positive effect on glucose metabolism (MacKenzie et al., 2018). As detailed in section IV.F, blockade of the central 5-HT3R results in a decrease of blood glucose levels, whereas antagonism at these receptors in the periphery leads to curtailed insulin secretion from pancreatic β-cells (Rahimian et al., 2013a). Indeed, based on animal studies, 5-HT3R has been proposed as a novel target to prevent obesity (Weber et al., 2009).

D. Drugs of Abuse

A common denominator of substances of abuse is their action to boost the mesolimbic DA pathway as an integral part of the reward system, thereby driving reinforcing and seeking effects (Pierce and Kumaresan, 2006). This pathway consists of dopaminergic neurons located in the VTA in the brain stem, sending their projections to limbic structures including the NAc and amygdala (Volkow and Morales, 2015). Such influence is exerted either through a direct action on components of the dopaminergic system as do psychostimulants (e.g., amphetamines and cocaine) or rather through nondopaminergic receptors that are part of the regulatory systems of this pathway, among which are 5-HT, GABA, and opioidergic systems (Engleman et al., 2008). Opiates stimulate the endogenous opioid receptors on GABAergic interneurons that inhibit mesolimbic DA neurons. Their resultant disinhibition leads to an enhancement of DA transmission within the mesolimbic system (Alex and Pehek, 2007).

1. Modulation of Neurotransmission. Because of the diversity of 5-HT receptor subtypes that transduce various signals and their distribution, 5-HT can give rise to a complex outcome. In the case of 5-HT3Rs, although they are expressed at very low densities across areas such as the NAc, VTA, striatum, substantia nigra, and DRN (Gehlert et al., 1991; Engleman et al., 2008), there are substantial electrophysiological and microdialysis data indicating that 5-HT3Rs influence DA activity in these regions. 5-HT3Rs modulate phasic DA release within the NAc, where they appear to be expressed preferentially on presynaptic dopaminergic terminals projecting from the VTA (Blandina et al., 1988; Mylecharane, 1996). Activation of 5-HT3 ion channels on these axons enhances calcium influx leading to liberation of DA into the NAc, thereby reinforcing reward. Antagonists, on the other hand, partially prevent drug-induced stimulation of mesolimbic DA release and decrease craving.

Early pieces of evidence for 5-HT3R antagonist indication in addiction go back to the late 1980s. These agents were shown to block morphine- and nicotine-evoked place preference conditioning (Carbone et al., 1989b), suggesting their effect in preventing the rewarding properties of both substances. In the same vein, 5-HT3R blockade counteracts morphine- and nicotine-induced DA release in the NAc (Carbone et al., 1989a; Imperato and Angelucci, 1989; Pei et al., 1993). Antagonism at 5-HT3R reduces ethanol consumption and disrupts response to ethanol in an ethanol discrimination task (Higgins et al., 1992) as a consequence of attenuating the ethanol-derived DA release in the NAc (Carbone et al., 1989a; Wozniak et al., 1990). Similar neurochemical effects as well as attenuation of place preference acquisition were observed with MDL 72222, a potent and selective 5-HT3 antagonist, when using cocaine and stimulant amines amphetamine and mazindol as reinforcing drugs (Kankaanpää et al., 1996, 2002). Various 5-HT3R antagonists inhibit benzodiazepine binding to both native and recombinant GABAA receptors and curtail the evoked chloride currents (Klein et al., 1994). However, MDL 72222 failed to influence measures of ketamine-provoked psychotomimetic effects in rodents (Kos et al., 2006). Figure 2 depicts the effects of 5-HT3R antagonists on neurotransmitter systems.

2. Clinical Findings. 5-HT3R antagonists have been used successfully in the treatment of alcoholism, especially early-onset alcoholism. In a double-blind, randomized placebo-controlled clinical trial, ondansetron was effective in reducing alcohol consumption in individuals with early-onset but not late-onset alcoholism (Johnson et al., 2000b). The same effect was repeated in a smaller male population over a shorter course of treatment (Kranzler et al., 2003). Ondansetron also reduced alcohol craving in these subjects (Johnson et al., 2002). Furthermore, ondansetron displayed additional effects on decreasing alcohol drinking (Johnson et al., 2000a) and craving (Ait-Daoud et al., 2001) in this population target when combined with naltrexone. In addition, twice-daily tropisetronin administered in a clinical trial conducted with cocaine users was beneficial in increasing cocaine-free days in the week (Colombo et al., 2006).

Nevertheless, despite promising preclinical findings on other drugs of abuse, 5-HT3R antagonists have failed clinically. When conducted with subjects with
benzodiazepine (Romach et al., 1998), nicotine (Hatsukami et al., 2003), amphetamine (Johnson et al., 2008), or opiate (Sell et al., 1995) use disorder, clinical trials reveal no effect by setrons on any aspect, including dosage, craving, or withdrawal symptoms, at least not with the therapeutic regimens practiced.

E. Other Neuropsychiatric Disorders

Although pharmacological assessment of a role for 5-HT₃Rs is lacking in other neuropsychiatric disorders, genetic studies have begun to unravel the significance of these receptors. In HTR3A and HTR3B, three functional SNPs (rs1062613, rs1176744, and rs3831455) have consistently been associated with bipolar disorder among different ethnic groups (Hammer et al., 2012). Epigenetic modification of HTR3A has also been implicated in the clinical severity of three psychiatric disorders. The DNA methylation status of the gene was associated with the severity of bipolar disorder, borderline personality disorder, and adult attention-deficit/hyperactivity disorder (Perroud et al., 2016).

VI. Concluding Remarks

Ligand-gated ion channels are the second most important targets for drug discovery only after G protein–coupled receptors. Various ligand-gated ion channel receptors, such as GABA_A, nicotinic, N-methyl-D-aspartate, P2X, and 5-HT₃, have been characterized thus far. The neuropharmacology of 5-HT₃Rs has been overshadowed by other members of this large family. One main reason is that the identification of 5-HT₃Rs did not occur until mid-1980s, owing to a lack of selective pharmacological tools. In the 1990s, 5-HT₃R antagonists revolutionized the treatment of chemotherapy-induced emesis. Nonetheless, other therapeutic potentials of this class were neglected for years until recent investigations demonstrated that these compounds could alleviate the pathology of certain neurodegenerative and neuropsychiatric disorders. As detailed in the previous sections, 5-HT₃R antagonists modulate neurotransmitters and their neural networks in brain regions associated with these conditions (Fig. 2). Setrons, via various mechanisms, can also counteract neuroinflammation, a phenomenon increasingly regarded as a centerpiece in the pathogenesis of neurologic and psychiatric disorders, as part of their protective properties. Interestingly and despite their anti-inflammatory actions, immunosuppression has not yet been reported with setrons.

However, a tantalizing potential of setrons is in the management of schizophrenia and alcohol use disorder. In clinical trials, setrons have shown promising effects against the most intractable symptoms of schizophrenia, namely negative and cognitive symptoms. Setrons have also been very successful in treating early-onset alcohol dependence. The condition is presumably associated with major serotonergic dysfunction, including overexpression of postsynaptic 5-HT₃R in the mesolimbic DA system (Johnson and Ait-Daoud, 2000). This is a particularly big advancement in the treatment of alcoholism, since this type presents as the most refractory to treatment and highly comorbid with psychosocial problems such as antisocial behaviors (Johnson and Ait-Daoud, 2000).

The lack of many adverse effects linked with conventional treatments available for psychiatric disorders such as abuse liability, sedation, glucose intolerance, and propensity to induce tardive dyskinesia (Fig. 3) is clinically relevant and can benefit patients suffering from psychiatric diseases. Given the advantageous therapeutic profile of 5-HT₃R antagonists combined with their broad therapeutic window, more detailed studies on this class of drugs could open avenues for the development of novel pharmacophores with higher efficacy and better compliance for the management of neurologic and neuropsychiatric disorders.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Fakhfouri, Rahimian, Dyhrfjeld-Johnsen, Zirak, Beaulieu.

References
5-HT3 Receptor Antagonists in Neurology and Neuropsychiatry


modulating the activation of JNKERK MAPK pathways. 


J Pharmacol Exp Ther 263: 457–463.


psychoysis, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry 9:622.


controlled double-blind trial of tropisetron for the prevention of chemotherapy symp- 
toms in chronic and stable schizophrenia. Psychopharmacology (Berl) 228:595–602.


tinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638.


Pate A, Mittal S, Manchanda S, and Puluiy MJ (2011) Ondansetron-induced dys-

Pate A, Ritzel R, McCallum LD, and Liu F (2013) Microglia and ischemic stroke: 


Pehson AL and Sanchez C (2014) Serotonergic modulation of glutamate neurotrans- 
mission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 19:121–133.


ADHD, borderline personality, and bipolar disorders: link with severity of the disorders and childhood maltreatment. Depress Anxiety 33:45–55.

Perry ER, Curtis M, Dick DJ, Candy J, Attack JR, Bloxham CA, Blessed G, Fair- 
Neurol Neurosurg Psychiatry 48:413–421.

5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors. J Physiol 588: 587–596.


Pettman M, Tran Van Ba C, Broussy A, Romanet C, and Dyhrfjeld-Johnsen J (2015) 5-HT3 receptors enhance hippocampal long-term depression via activation of AMPARs and ischemic stroke: a controlled prospective study of tropisetron added to 
risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. 

Pezron SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, and Hilt DC (2014) 

5-HT2A, and 5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopaminergic transmission and reduce nociceptive behavior in rats. 


Rahimian R, Dehpour AR, Fakhroui G, Khormazizadeh MR, Ghia J, Rieysebad M, 
Maldarelli A, Moussazadeh K, Forouzandeh M, and Mehr SE (2011b) Tropi- 
setron upregulates cannabinoid CB1 receptor in cerebral granule cell: possible 

Acta Med Iran 51:736.


Van Nuen 3:467–490.


